Prospective Study Comparing Acute Toxicity and Objective Response Rate between Simultaneous Integrated Boost and Sequential Boost Intensity-Modulated Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Prospective Study Comparing Acute Toxicity and Objective Response Rate between Simultaneous Integrated Boost and Sequential Boost Intensity-Modulated Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Prospective Study Comparing Acute Toxicity and Objective Response Rate between Simultaneous Integrated Boost and Sequential Boost Intensity-Modulated Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma Sahar Samy Abo El-Atta, Alaa Mohamed Maria, Lamiss Mohammed Abd-Elaziz, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7041401/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 15 Nov, 2025 Read the published version in Medical Oncology → Version 1 posted 11 You are reading this latest preprint version Abstract Purpose Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) were included for evaluation of patient’s characteristics, dosimetric analysis and plan evaluation of both intensity-modulated radiotherapy (RT) using simultaneous integrated boost (SIB-IMRT) and sequential IMRT (IMRTSEQ) and compare the response and acute toxicity of both arms. Materials and Methods This prospective single blind randomized clinical comparative study was carried out on 60 patients, clinically and histologically confirmed of locally advanced HNSCC at Clinical Oncology Department, Tanta University Hospitals. All patients were randomly divided into two equal groups: Group A was treated with SEQ-IMRT and group B was treated with SIB-IMRT. All patients received 3 cycles induction chemotherapy with (Docetaxel or Taxotere), Platinum and 5-fluorouracil followed by concurrent chemo RT with cisplatin or carboplatin. Results Performance status 2; Organ at risk (OAR) was higher for group B (63.6%) vs. (18.2%), (p = .030). post cricoid subsite, OAR was higher for group B (100%) vs. (33.3%) for group A, (p = 0.035). For N2 patients, OAR was higher in group B (66.7%) than group A (35%), (p = 0.043) with CR was in (33% vs. 20%)) for group B &A respectively, (p = 0.241). Conclusion The SIB-IMRT arm, with shorter total treatment duration, resulted in comparable treatment outcomes and acute toxicity rates. This reduction in treatment time not only reduces costs but also decreases the workload of busy radiation. The SIB-IMRT is well-tolerated with better treatment-compliance for head and neck cancer patients. Acute Toxicity Response Rate Simultaneous Integrated Boost Sequential Boost Intensity-Modulated Radiation Therapy Advanced Head and Neck Squamous Cell Carcinoma Figures Figure 1 Figure 2 Figure 3 Figure 4 Introduction Head and neck malignancy is a disease that is remarkably heterogeneous, encompassing epithelial malignancies that develop in the paranasal sinuses, nasal cavity, oral cavity, pharynx, and larynx [ 1 ]. Nevertheless, there is a growing body of evidence that human papillomavirus is responsible for a specific subset of head and neck squamous cell carcinomas (HNSCC). The improvement of survival outcomes for locally advanced disease remains a significant challenge [ 2 ]. Radiotherapy (RT) and surgery have been the primary treatment methods for an extended period of time [ 3 ]. RT is a critical component of curative treatment strategies in locally advanced HNSCC (LAHNSCC), both in the definitive phase (in the event of inoperability or to prevent mutilating surgery in oropharyngeal cancer) and in the postoperative adjuvant phase. Concomitant chemotherapy, which is typically based on cisplatin, enhances the prognosis in the definitive and postoperative adjuvant settings, particularly in the presence of extracapsular nodal spread or microscopically involved resection margins [ 4 ]. Head and neck cancers (HNC) are associated with greater recurrence rates, particularly in advanced stages. Areas that received a median radiation dose of 67 Gy are responsible for 45% of loco-regional failure [ 5 ]. Consequently, it is postulated that certain subgroups of HNC patients would benefit from an intensified local treatment, such as the escalation of radiation dose [ 6 ]. The potential to deliver higher target doses without necessarily giving higher doses to organs at risk is feasible due to technical advancements, such as the development of intensity-modulated RT (IMRT). This has made it possible to achieve more conformal dose distributions [ 7 , 8 ]. The sequential boost technique and the simultaneous integrated boost (SIB) are dose delivery strategies that are implemented in both volumetric modulated arc therapy and step and shot IMRT. The criteria for selecting one or the other method are typically subjective, and there are no clear recommendations for patient selection. However, the biological effects of irradiation may be advantageous for one technique or another, as determined on a case-by-case basis. Both strategies are employed in daily clinical practice [ 9 , 10 ]. The aim of this work was evaluation of patient’s characteristics, dosimetric analysis and plan evaluation of both intensity-modulated RT (IMRT) using sequential IMRT (IMRTSEQ) and simultaneous integrated boost (IMRT-SIB) and compare the response and acute toxicity of both arms. Materials and Methods This prospective single blind randomized clinical comparative study was carried out on 60 patients, clinically and histologically confirmed of with LAHNSCC at Clinical Oncology Department, Tanta University Hospitals during the period from January 2022 to December 2023. An informed written consent was obtained from the patients. The study was done after approval from the Ethics Committee of the Faculty of Medicine, Tanta University Hospitals (35092/12/21). Inclusion criteria were age more than 18 years old, patients with locally advanced radiologically and histologically confirmed stage III, IVA squamous cell carcinoma of oral cavity, hypopharynx and larynx according to 8th edition 2018 American Joint Committee on Cancer (AJCC) Tumor, Node, Metastasis staging with no previous surgery, chemotherapy or RT [ 11 ], performance status 0 to 2 according to Eastern Cooperative Oncology Group (ECOG) score and adequate organs' functions including (haematological, hepatic and renal function tests) [ 12 ]. Exclusion criteria were performance status more than 2, other malignancy including nasopharyngeal carcinoma or second primary, patients with severe arrhythmia, active infection or active peptic ulcer, uncontrolled diabetes mellitus or other uncontrolled medical illness, congestive heart failure or myocardial infarction within 6 months and patients treated with high dose corticosteroids (20mg of prednisone or equivalent) during last 6 months. Randomization : Randomization was implemented through a computer-generated system. After obtaining the patient's consent, the list was concealed in sealed envelopes that were numbered and opened sequentially. All patients were randomly divided into two equal groups: Group (Arm) A (n = 30): was treated with SEQ-IMRT with combined total doses in phase I, II and III 70 Gy/ 35 fractions, 2 Gy/fraction along the all course, 5 days a week, in 7 weeks by 54 Gy in 27 fractions to planning target volume-low risk (PTV-LR), planning target volume- intermediate risk (PTVIR) and planning target volume- high risk (PTV-HR) in phase I followed by shrinking the field to cover only (PTV-IR) and (PTV-HR) by 60 Gy in (6 GY in 3 fractions) in phase II followed by 10 Gy in 5 fractions to PTV-HR only in phase III to be covered by 70 Gy. Group (Arm) B (n = 30) was treated with SIB-IMRT with dose 66 Gy to PTV-HR (2.2 Gy /fraction), 56 Gy to PTV-LR (1.8 Gy/ fraction) and 60 Gy to PTV-IR (2 Gy/fraction), all volumes in 30 fractions, 5 days a week, over 6 weeks. Pretreatment evaluation : All included patients were subjected to history taking including personal history (age, sex), habits (smoking and/ or alcohol), complaint (symptoms), family history of such illness and past history of surgery and medical illness, general examination (weight, height & performance status according to ECOG scores) [ 12 ] and local examination (inspection & palpation., cranial nerve examination, indirect laryngoscopy, fibro optic endoscopy and neck node evaluation), radiological imaging including (diagnostic magnetic resonance imaging (MRI) or high-resolution computed tomography (CT) head and neck with contrast, contrast enhanced CT chest, pelvi-abdomenal ultrasonography with CT abdomen and pelvis with contrast, bone scan, fluorodeoxyglucose positron emission tomography/computed tomography scan, electrocardiogram & echocardiogram, laboratory investigations (complete blood picture, renal function tests, liver function tests and serum electrolytes, invasive tests (biopsy) [meticulous clinicoradiological tumor mapping by oncology and Otorhinolaryngology consultant with histopathological evaluation of primary site and/ or enlarged lymph node, staging according (AJCC) 8th edition [ 11 ]], nutritional assessment by oncology dietitian with assessment of nutritional risk based on the use of anthropometric measurement of weight, height, body mass index (BMI) and percentage of body weight loss [ 13 ], and pretreatment dental care. Treatment approach : Induction chemotherapy (IC): the platinum-based regimen (TPF) was administered to all patients in three cycles. The regimen consisted of docetaxel at a dose of 75 mg/m2 administered as a 1-hour infusion on day 1, cisplatin at a dose of 75 mg/m2 administered as a 1-hour infusion on day 1, and 5-fluorouracil at a dose of 750 mg/m2 per day, administered by continuous infusion on days 1 to 5. Treatment was administered every three weeks. Weekly cisplatin at a dose of 40 mg/m2 was administered concurrently with chemotherapy. The maximal dose was restricted to 70 mg. Carboplatin was given for 9 patients who developed increase serum creatinine during CCRT by dose AUC = 2 / weekly. A pre-hydration of 2 liters of fluids was administered to the patients. The post-hydration saline with manitol was supplemented with 10 mmol of magnesium sulfate and 20 mmol of potassium chloride. A standard prophylactic anti-emetic that combines dexamethasone and 5hydroxytryptamine-3. To prevent hypersensitivity reactions and mitigate docetaxel-related cutaneous toxic effects and fluid retention, dexamethasone (at a dose of 8 mg) was administered every 12 hours for a total of six doses, commencing the night before the administration of chemotherapy (TPF) and concluding the day after. Prophylactic granulocyte colony-stimulating factor was permitted after each cycle as possible with prophylactic antibiotic. RT: patients were treated in the supine position while the arms are aside. CT simulation of the head and neck was done with slice thickness 3–5 mm from vertex to D10-11 vertebrae then CT data were imported to the contouring and planning system. In accordance with the International Commission on Radiation Units and Measurements (ICRU) Report 83, the gross tumor volume (GTV) was defined by contouring gross visible tumor and enlarged or suspicious lymph nodes that were identified through clinical examination, endoscopy, and CT scan or MRI scan imaging [ 14 ]. GTV with a margin of 0.5–1.0 cm for subclinical microscopic malignant disease was contoured as CTV-high risk (CTV-HR). The entire level was incorporated into CTV-HR for nodal levels that were involved. The Radiation Therapy Oncology Group (RTOG) contoured and delineated low-risk areas with potential subclinical microscopic disease as CTV-low risk (CTV-LR). These areas routinely include bilateral level II–IVA lymph nodes, while level IVB was included if level IVA was positive [ 15 ]. A margin was established around the CTV to account for the uncertainties of RT planning, treatment delivery, patient set-up, and tissue deformation. This margin was designated as the planning target volume (PTV). To define each PTV-high risk (PTV-HR), PTV-intermediate risk (PTV-IR), and PTV-low risk (PTV-LR), an isotropic expansion of 5 mm was incorporated around the CTV. Within the body contour, the treatment planning system automatically cropped the PTV-HR, PTV-IR, and PTV-LR by 3 mm to disregard the initial superficial millimeter that corresponds to the build-up region, with the exception of regions where the skin was deemed to be a component of the CTV. Dose description: The dose prescription in group A (SEQ-IMRT) was 54 Gy in in 27 fractions to (PTV-HR, PTV-IR and PTV-LR) in phase I followed by 6 Gy in 3 fractions to (PTV-HR and PTV-IR) in phase II followed by 10 GY in 5 fractions to PTV-HR in phase III (combined total doses in phase I, II and III was 70Gy in 35 fractions, 5days of week in 7 weeks and 2 Gy/ fraction in all phases). While in group B (SIB-IMRT), dose was 66Gy to PTV-HR (2.2 Gy / fraction), 60 Gy to (PTV-IR) 2 Gy/fraction and 54 Gy to PTV-LR (1.8Gy / fraction), all were given at the same time in 30 fractions, 5 days a week, over 6 weeks. The OAR dose-constraints were prescribed as per the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) guidelines [ 16 ]. Dose constraints for OARs were maximum dose to the spinal cord (Dmax) < 45 Gy, brain stem Dmax < 54 Gy, mean dose to bilateral parotid < 26 Gy, mandible Dmax < 70 Gy and oral cavity Dmean < 40 Gy. All constraints were used for SEQ-IMRT group and SIB-IMRT in all patients. Treatment planning was conducted using the Eclipse 13.7 treatment planning system from Varian. The Varian Trilogy linac, which is equipped with a 120 leaf Millennium Multileaf Collimator (MLC), produced 6 MV photon beams (MLC). Each IMRT plan used 9 coplanar beams. Initially, the treatment planning system was loaded with a set of initial optimization targets, and the beam angle optimization method was used to optimize the IMRT beam angles. The dosimetrists' expertise informed the adjustment of many beam angles. After inverse planning, the leaf sequences using sliding window technique were generated for IMRT plans. In accordance with ICRU report 83 [ 14 ]. Homogeneity index (HI) as well as Conformity index (CI) were calculated for every plan. The HI was determined by subtracting the doses given to different portions of the target volume - the lowest dose to the 98 percent, the maximum dose to the 2 percent, and the median absorbed dose to the 50 percent - using the formula: HI = (D 2% - D 98%)/D 50%. When the HI was zero, it meant that the dosage distribution was very consistent. A bigger HI might mean that the dosage was either too high or that the target volume was getting an inadequate dose [ 17 ]. The equation: CI = (PTVref/PTV) × (PTVref/ ref) was employed to define the CI. Vref denotes the organ volume that is contained within the prescribed isodose line. On the other hand, PTVref quantifies the coverage of PTV by this isodose line. 1 was the optimal value, and the CI ranged from 0 to 1. a prescription dose that was delivered outside the PTV was of a lower volume, as indicated by a larger CI. As the CI value approaches 1.0, the dose conformity improves [ 17 ]. The coverage of PTV was set to at least 95% of the PTV volume covered by the 95% prescribed dose, minimize volume receiving > 110% of prescribed dose to < 1%. Any treatment gaps were managed as per Royal College of radiologists guidelines, aiming to complete RT within 6–7 weeks [ 18 ]. Follow-up : Patients were followed up weekly for acute radiation or chemotherapy toxicity symptoms and signs with assessment of mucositis, dermatitis, xerostomia and dysphagia at week (2, 4 and 6) of RT consistent with the common terminology criteria for adverse event (CTCAE version 5.0) and RTOG [ 19 , 20 ]. The patients were encouraged to maintain their weight by modifying the diet and engaging in physical activity, such as a daily walk or home training sessions, for a duration of 10–60 minutes, three times per week, during the course of treatment. Body weight was monitored on a weekly basis. Every patient who experienced regurgitation, fungal mouth infection, or mucositis received appropriate treatment to enhance oral intake. Oral nutritional supplements were administered to patients who were unable to meet their daily nutritional needs. Clinical assessment was conducted on a monthly basis for the initial three months, three times per month for the first two years, and six times per month thereafter. This assessment was conducted through a history and examination. Patients were compared as regard to clinicopathological characteristics, dosimetric parameters, acute & late toxicities, treatment response with comparison with different clinicopathological parameters and survival outcome including overall survival (OS), progression free survival (PFS) and disease free survival (DFS) with comparison with to clinicopathological parameters. Clinical outcomes : Assessment of tumor response: CT/MRI Head and Neck and direct laryngoscopy beside clinical examination were done at 2 months after completion of treatment to assess the response According to Response Evaluation Criteria in Solid Tumors, version 1.1 criteria (RECIST 1.1) (Appendix 5) [ 21 ]. Tumor response was evaluated with different prognostic factors. Assessment of toxicity: The occurrence and nature of any adverse events were recorded during CCRT. Acute toxicity (up to 6 months post-treatment) and late toxicity (beyond 6 months) from the chemoradiation including mucositis, dermatitis, dysphagia and xerostomia were assessed and graded based on (CTCAE version 5.0) and RTOG [ 19 , 20 ]. Assessment of survival: OS is defined as the time from randomization to death. Any patients lost to follow up or still alive at the time of evaluation are censored [ 22 ]. DFS is defined as any locoregional persistence or recurrence after RT or distant metastasis at any time or death from current disease at any time [ 23 ]. PFS is the duration from the time of randomization until the first indication of disease progression or mortality. Patients who are alive at the time of evaluation or who were lost to follow-up are included in the calculation of PFS through censoring [ 24 ]. Both arms were compared as regard OS, PFS and DFS with comparison with different prognostic factors. Statistical analysis: The SPSS software statistical computer application for Windows, version 25.0 (Armonk, NY: IBM Corp), was employed to statistically analyze the collected data, which was organized and entered into an Excel sheet. The mean, standard deviation, and range were used to represent parametric quantitative data that was normally distributed [ 24 ]. The median and interquartile ranges (25th-75th percentiles) were used to represent nonparametric quantitative data that was abnormally distributed [ 25 ]. Qualitative data were presented by number and percent. The results were tabulated, grouped and statistically analyzed using the following tests: Independent t Test (t) [ 26 ], Mann Whitney U Test (U) [ 27 ]. Pearson Chi Square Test (χ²): when it was inappropriate, it was replaced by Fischer Exact or Monte Carlo Exact test [ 28 ]. P value used to indicate the level of significance: P > = 0.05: Non-significant, P < 0.05: Significant and P < 0.001: Highly significant. OS, PFS and DFS Survival plots and cumulative survival probabilities were estimated using the Kaplan-Meier method [ 29 ]. Case presentation Case 1: Male patient aged 48 years old, PS 0, with left trans glottic mass involving the whole length of left vocal fold (VF) with extension to vestibular band & anterior commissure with minimal subglottic extension (3-5mm), squamous cell carcinoma grade II, stage IVA T2N2bM0, Patients was treated with 3 cycles induction CTH (TPF) with PR followed by CCRT with cisplatin with SIB-IMRT (66 Gy) for PTVHR, (60 Gy) for PTVIR & (54 Gy) for PTVLR. The PTVHR volume was 32.8 cm3, with CI= 0.95, HI= 0.06, achieved radiological CR after CCRT with G1 dermatitis & xerostomia, G2-3 mucositis & dysphagia with preserved post treatment BMI. Fig. 1 Case 2: Female patient aged 44 years old, PS 0, with bilateral internal jugular LNs, squamous cell carcinoma grade II, stage IVA T2N2cM0. Patient was treated with 3 cycles induction CTH (TPF) with PR of the PCC mass and CR of LNs, followed by CCRT with cisplatin with SEQIMRT (70 Gy) for PTV HR& (60 GY) for PTVIR. The PTV HR volume was 88 cm3, with CI=0.98, HI=0.02, achieved radiological SD after CCRT with G2 dermatitis, xerostomia, mucositis & dysphagia with preserved post treatment BMI. Fig. 2 Results In this study, 93 patients were assessed for eligibility, 24 patients did not meet the criteria and 9 patients refused to participate in the study. The remaining 60 patients were randomly allocated into two groups (30 patients in each). All allocated patients were followed-up and analysed statistically. Fig. 3 There was no significant difference in clinicopathological parameters and type of concurrent chemotherapy between the patients for both groups of the study. Table 1 Regarding the maximum dose point (Dmax) in all PTVs, it was higher in group A than in group B but only statistically significant in PTVHR with (P = 0.013). Mean Dmax (Gy) was (72.59 ± 3.33) (63.3 ± 3.97) and (58.46 ± 4.01) vs. (67.12 ± 2.60) (62.7 ± 2.76) (57.51 ± 4.52) for (PTVHR, PTVIR and PTVLR) for group A and B respectively. The minimum dose point (Dmin) was lower in group A than in group B with statistical significance in PTVHR, PTV IR and PTV LR, (p= 0.003, < 0.001 & 0.013) respectively. The mean Dmin (Gy) were (65.73 ± 1.80) (56.46 ± 1.69) and (52.86 ± 1.65) vs. (62.89 ± 1.67) (57.54 ± 1.72) and (53.48 ± 1.86) for (PTVHR, PTVIR and PTVLR) group A & B respectively). There was insignificant difference regarding the mean dose (Gy) between both groups in all PTVs, in PTVHR, in PTVIR and in PTVLR, for group A and B. As regard target coverage, D95% was lower in PTVHR, PTV IR and PTV LR in group A than in group B with mean D95%(Gy) respectively with statistical significance only in PTV HR D95%, (P =0.001). The volume of each target was insignificantly different for both groups except in PTVHR, it was significant with median volume (79.4 cm3) vs. (49.1 cm3), p= 0.012. PTV IR, median volume was (387.45cm3) vs. (457.0 cm3), and (112.5 cm3) vs. (287.0 cm3), p= 0.093 for PTV LR for group A and B respectively. As regard dose homogeneity, HI was significantly higher in group A in all PTVs than group B, with median HI (p=<0.001) in PTVHR, (p= 0.005) in PTVIR and (0.2 vs. 0.1, p= 0.012) in PTVLR. CI was significantly lower in group A than in group B in all PTVs with (P <0.001). As regard mean dose to esophagus, it was higher in group B than group A, while mean dose to oral cavity was higher in group A than group B respectively. The mean Dmax to spinal cord was higher in group B than in group A, while the mean dose to each parotid in both groups was nearly the same for right parotid and for left parotid for group A & B respectively. Table 2 All patients received 3 cycles of IC with TPF every 3 weeks, followed by CCRT. Toxicity to induction CTH (TPF), 14 patients (23.4 %) suffered from G1-2 stomatitis with oral ulceration & pain. Grade 2 vomiting was presented in 5 patients (8.3%). Increase in liver enzymes (1.5 to 5) upper limit normal and G1 neuropathy were in 6 patients (10%) for each toxicity. Patients developed G2 nephrotoxicity were 5 patients (8.3%) after 3 cycles induction TPF and continued their concurrent chemotherapy with carboplatin with renal support and good hydration. Grade 1 hepatotoxicity was in 6 patients (10%) and haematological toxicity with G3 neutropenia was in 13 patients (21.6%) and G1 thrombocytopenia was in 9 patients (15%). Regarding acute mucositis, it was more prominent in group B but without statistical significance, there were more G 2 and G3 mucositis in group B and A respectively. Similarly, acute dermatitis was higher in group B than group A without statistical significance. While as regard acute dysphagia, there was statistically significant more dysphagia in group B than in group A at the end of 4 and 6 weeks with (P = 0.024 and 0.32) respectively. Acute xerostomia was more in group A than in group B but statistically insignificant. Renal impairment with increase serum creatinine and sensory neuropathy due to concurrent platinum (cisplatin) were statistically insignificant for both groups. Table 3 There was comparable weight loss due to RT toxicity for both groups of the study. As regard post treatment BMI, 5 patients (16.7%) in group A vs. 7 patients (23.3%) in group B were < 18.5 Kg/m2, with 3 patients (10%) needed nasogastric tube for feeding in group A vs. one patient (3.3%) in group B and only one patient in group A needed gastrostomy for feeding vs. no patients in group B after failure of oral and IV nutritional supportive treatment. Patient hospitalized for supportive treatment for RT toxicity were more in group B 12 patients (40%) vs. 10 patients (33.3%) in group A with good IV hydration, oral hygiene and nutritional supportive treatment were given according to grade of toxicity and weight loss. Compliance to treatment during CCRT, median time of interruption in the course of treatment was more in group A than in group B with which was more due to RT toxicity. There was insignificant difference between both arm of the study regarding acute (dermatitis, mucositis, dysphagia and xerostomia), where G2 acute dermatitis was more in group B than in group A while G2 acute mucositis was higher in group A than group B. Regarding G2 acute dysphagia, it was higher in group B than group A, While G2 acute xerostomia was more in group A than in group B. Acute neuropathy was comparable between both groups. Late toxicity to CCRT after 6 months of follow up, where G1-2 late dermatitis was higher in group B than in group A. While G1-2 late xerostomia and hoarseness of voice (laryngitis) were more common in group A than for group B. Table 4 After induction chemotherapy, OAR for all patients was 37/60 patients (61.7%) with CR in 1/60 patient (1.7%). The OAR after CCRT was 40/60 patients (66.7%) for the whole group with higher OAR for group B than group A with 23/30 patients (76.7%) vs. 17/30 patients (56.7%) respectively. Complete response was reported in 21/60 patients (35.0%) for whole with higher CR for group B 13/30 patients (43.3%) vs. 8/30 patients (26.7%) for group A. As regard the age, OAR was higher for group B (87.5% vs. 75%) for group A in age group = 62 years, OAR was higher for group B (64.3% vs. 44%) for group A, with CR (35.7% vs. 11.1%) for group B and A respectively. As regard the sex, OAR was higher in group B (73.1% vs. 56.5%) for group A in male patients, with CR was reported in (42.3% vs. 30.4%) for group B &A respectively. For female patients, OAR was reported in (100% vs. 57.1%) for group B and A respectively, with higher CR in group B (50% vs. 14.3%) for group A. As regard the PS, OAR was equal in patients with PS0 (100%) for both groups with higher CR for group B (85.7%) vs. (60%) for group A. The same for patients with PS1, OAR was higher for group B (75%) vs. (71.4%) for group A, with also higher CR for group B(33.3%) vs. (28.6%) for group A. Also for PS2, OAR was higher for group B (63.6%) vs. (18.2%), with CR (27.3% vs. 9.1%) for group B and A respectively. As regard smoking habit, OAR was higher for group B than group A (85.7%) vs. (57.1%) respectively for non-smoker, with CR was reported in (28.6%) vs. (14.3%) for group B &A respectively. Also in light smoker, OAR was higher for group B (100%) vs. (90%) for group A, with CR was reported in (58.3%) vs. (50%) for group B& A respectively and in heavy smoker, OAR was also higher for group B (45.5%) vs. (30.8%) for group A with nearly equal CR for both groups. Table 5 As regard the primary tumor site, OAR was higher for group B than group A in oral cavity (oral tongue cancer) patients, with no CR was reported in any group. Also in laryngeal cancer patients, OAR was higher for group B (75%) vs. (65%) for group A, with CR was in (45%) vs. (40%) for group B & A respectively, the same in hypopharyngeal cancer patients, OAR was higher in group B than group A with CR in (50%) vs. (0.0%) for group A. Supraglottic subsite, OAR was higher in group B (72.7%) vs. (62.5%) for group A with CR (45.5% vs. 31.3%) for group B and A respectively. Glottic subsite, OAR was nearly equal for both groups (77.8% vs. 75%), however CR was higher in group A (75%) than in group B (44.4%). pyriform sinus subsite, OAR was higher in group B (66.7%) vs. (50%) for group A, with CR was in (33.3%) in group B vs. (0.0%) for group A. Post cricoid subsite, OAR was higher for group B (100%) vs. (33.3%) for group A, with CR was in (60%) for group B vs. (0.0%) for group A. Table 6 As regard the grade, OAR and CR were equal (100%) for both groups in G1 patients. While for G2 patients OAR was (88.2% vs. 72.2%) for group B and A respectively with (41.2% vs. 22.2%) were CR in group B and A respectively. The OAR for grade 3 was also higher in group B (44.4%) than in group A (11.1%), with (2 2.2%) vs. (11.1%) were CR in group B and A respectively. T stage, OAR was higher for group B (100%) vs. (37.5%) for group A for T2 patients, with CR was in (85.7%) for group B vs. (25%) for group A, while for T3 patients, OAR was higher for group A (69.2%) than in group B (64.3%), but with higher CR for group B (35.7%) vs. (30.8%) for group A. For T4a patients, OAR was higher for group B (776.7%) vs. (55.6%) but with equal CR for both groups (22.2%) for both groups. N stage, OAR was equal (100%)l for both groups with CR was higher in group B (66.75) vs. (28.6%) for group A. No patients with N1 disease in group B for comparison with A. For N2 patients, OAR was higher in group B (66.7%) than group A (35%), (p= 0.043) with CR was in (33% vs. 20%)) for group B &A respectively. Tumor stage, OAR was equal (100%) and equal CR (66.7%) in both groups in stage III, while in stage IVA, OAR was higher in group B (70.8%) vs. (45.8%) in group A with CR was in (37.5%) vs. (16.7%) in group B &A respectively. Concurrent chemotherapy with RT, OAR was higher in group B (84.6%) vs. (60%) for group A in patients received cisplatin with CR was in (50% vs. 32%) for group B and A respectively, while in patients received carboplatin, OAR was higher for group A (40%) vs. (25%) for group B with with no CR in either group. As regard gap of interruption during RT, OAR was higher for group B (80%) vs. (78.6%) for group A in patient without gap with with CR was in (45%) vs. (42.9%) for group B & A respectively, also in patients with gap of interruption during RT, OAR was higher in group B (70%) vs. (37.5%) for group A with CR was in (40% vs.12.5%) for group B &A respectively. Table 7 All patients were followed up for median period 20 months with 19.5 months for group A & 20 months for group B. For whole patients, 48/60 (80%) were alive (23/30 (76.7%) patients in group A and 25/30 (83.3%) patients in group B) with 6 patients died from residual disease and 4 died from recurrent disease and rest of 2 patients died due to unrelated causes. For whole patients, median OS was not reached with mean OS was 28.12±1.28 months, while mean OS were 26.835±1.637 months and 29.627±1.747 months for group A and B respectively. The 1-year & 2-year OS for whole group were (98.3% & 61.5%) respectively, while for group A and group B, 1-year OS was 96.7 % for group A vs. 100.0% for group B and the 2-year OS was 53.2% for group A vs. 71.2% for group B. The relation of one year OS to different clinicopathological parameters, type of concurrent chemotherapy, response state or gap of interruption during RT treatment, it was statistically insignificant. Fig. 3A-B Median PFS was not reached for whole group with mean PFS was 26.956± 1.409 months while for group A, mean PFS was 23.455±1.37 months (95% CI 20.77-26.14) and 23.529± 1.82 months for group B. The 1-year PFS was 88.3% for whole group and 86.7% for both group of the study, while the 2-year PFS was 58.3% for whole group and 49.4% vs. 69.2% for group A and B respectively. The relation of PFS to different clinicopathological parameters, type of concurrent chemotherapy, response state or gap of interruption in RT treatment, it was statistically insignificant. Fig. 3C-D As regard DFS of patients who achieved complete response after CCRT, median DFS was not reached for whole group with mean DFS was 31.97± 1.65 months for whole group, 30.43±2.74 months for group A and 32.92±1.99 months for group B. One-year DFS was 95.2% and 2-year DFS was 84.3% for all patients, while for group A, 1-year DFS was 100.0% for group A vs. 92.3% for group B and at 2-year, DFS was 71.4% for group A vs. 92.3% for group B. The relation of DFS to different clinicopathological parameters, type of concurrent chemotherapy, response state or gap of interruption in RT treatment, it was statistically insignificant. Fig. 3E-F Discussion Hypofractionated RT as SIB offers several advantages as condensed treatment schedule, reduces the overall treatment duration and enhances patient convenience and compliance [ 30 ]. In our study, no significant differences in patients' or tumor characteristics were found between both groups as regard age, sex, performance, smoking, comorbidities, tumor site, T stage, N stage, stage and grade (all p > 0.05). Most patients in both arms were males 76.7% vs. 86.7% with median age was 63.5 & 59.5 years and 60% vs. 46.7% were > = 62 years. In the study of SIKDAR et al., [ 31 ] 97% vs. 93.3% where male with median age was 60yrs vs. 57yrs for SEQ and SIB group respectively. Smokers were 76.7% of each group with 43.3% vs. 36.7% were heavy smoker in SEQ & SIB group respectively. In the study of Tripathy et al., [ 32 ] 76.9% vs. 81.8% were smoker in CFRT and accelerated hypofractionated RT (AHRT) respectively. Regarding performance status, 63.4% of patients in our study were with good performance status (score 0 and 1) for each group. Manni et al.,[ 33 ] reported that 82.4% vs. 76.5% were of KPS 80 in SEQ and SIB group respectively. Larynx was the most common primary tumor site (66.7%) for each group in our study. Vlacich et al., [ 34 ] reported that oropharynx was the most common primary tumor site 71% vs. 59% for SEQ and SIB group respectively. As regard T3 disease, it was the predominant in our study, 43.3% vs. 46.7%, in SEQ and SIB group respectively. Sikdar et al., [ 31 ] reported that 36.4% vs. 48.5% were T3 for SEQ and SIB group respectively. The N2 disease in our study was 66.7% vs. 70% for SEQ & SIB group respectively. Sikdar et al., [ 31 ] reported that 45.5% vs. 48.5% were N2 for SEQ and SIB group respectively. Patients with stage IVA disease were 80% in each group of the study. Tripathy et al., [ 32 ] reported that 64.6% vs. 67.3% had Stage IV disease for CFRT and AHRT respectively. All patients in our study were SCC with G2 tumor was the most common in the pathology 60% vs. 56.7% for SEQ and SIB group respectively. Mani et al., [ 33 ] reported that grade1 was the most common 353% vs. 52.9% in SEQ and SIB group respectively. The mean Dmax was 72.59 Gy vs. 62.89 Gy, (P = 0.013), for PTVHR and 58.46 Gy vs. 53.48 Gy, for PTVLR in SEQ and SIB group repectively. Rakesh et al., [ 35 ] reported that Dmax was 74.9 Gy vs. 71.98 Gy, (P < 0.001) for PTVHR and 75.30 Gy vs. 71.98 Gy, (P < 0.001) for PTVLR for SEQ and SIB respectively. Regarding mean dose in our study, no statistical significance difference between both groups with 68.95 Gy vs. 64.6 Gy, for PTVHR and 56.50 Gy vs. 56.17 Gy, for PTVLR, for SEQ and SIB group respectively. Rakesh et al., [ 36 ] reported that Dmean was 69.23Gy vs. 66.15 Gy, P = 0.012 for PTVHR and 70.24 Gy vs. 67.13 Gy, P < 0.001 for PTVLR for SEQ and SIB group respectively. As regard to target coverage, mean D95% (Gy) was 67.41 Gy vs. 65.47 Gy, (p = < 0.001) for PTVHR and 54.77 Gy vs. 54.99 Gy, (p = 0.470) for PTVLR P for SEQ and SIB group respectively. Sikdar et al., [ 31 ] reported that PTVHR D95% was equal for both SEQ and SIB group 98.18% vs. 98.08% respectively. In our study, the volume of each target was insignificantly different between both groups except for PTVHR, the median volume was 79.4 cc for SEQ group vs. 49.1 cc for SIB group, (P = 0.012). Sikdar et al., [ 31 ] reported that median PTVHR volume was 197.2 cc in the SEQ arm and 174.5 cc in the SIB arm. Heterogeneity in dose distribution was more in the SEQ group than for SIB group with median HI 0 was 0.16 vs. 0.06, (p = < 0.001) for PTVHR and0.2 vs. 0.1, (p = 0.012) for PTVLR. Skidar et al., [ 31 ] reported more heterogenous dose in the SEQ-IMRT arm with median HI was 0.059 vs. 0.065 in SIB-IMRT. We found better conformity and sparing of organ at risk in the SIB group than in SEQ group with median CI was 0.86 vs. 0.96 for PTVHR and0.815 vs. 0.925 for PTVLR, (p = < 0.001) for all PTVs. Skidar et al., [ 31 ] reported that SEQ-IMRT median CI was slightly better 0.71 vs. 0.68 in SIB-IMRT. As regard mean dose (Gy) to the esophagus, it was lower for SEQ group 28.2 Gy than for SIB group 29.9 Gy, (p = 0.391). In agreement with Vlacich et al., [ 34 ] who reported that mean dose to esophagus was lower for SEQ group 25.6 Gy than for SIB group 27.2 Gy, (p = o.19). But in contrast with Grover et al., 2021 who reported that mean dose to esophagus was higher for SEQ group 26.1Gy than for SIB group 23.4Gy. While for mean dose to oral cavity, it was higher for SEQ group 29.2Gy than for SIB group 26.3Gy. In contrast to Grover et al., [ 37 ] who reported nearly equal dose to oral cavity with mean dose 37.9Gy vs. 38.5Gy for SEQ and SIB group respectively The mean Dmax to spinal cord was slightly lower for SEQ group 38.4Gy than for SIB group 39.7Gy, while Skidar et al., [ 31 ] reported that dose to spinal cord was 42.62 Gy vs. 41.6 Gy for SEQ and SIB group respectively. The mean dose to each parotid for both groups was nearly the same with 22.1 Gy vs. 21.6 Gy, and 21.58 Gy vs. 21.7 Gy, for right and left parotid SEQ and SIB group respectively. In contrast with Skidar et al., 2024 who reported higher dose to parotid especially SEQ group 36.14 Gy vs. 29.87 Gy, p = 0.073 for SEQ and SIB group respectively which may be also explained by higher oropharyngeal cancer patients in this study which near site to parotid glands. In our study, after 3 cycles TPF given to all patients before CCRT, the most common adverse events were G3 neutropenia (21.6%) and G1 thrombocytopenia (15%) and G2 stomatitis (mucositis) (11.7%) compared to Zhang et al., [ 38 ] where Neutropenia was 15.2%, thrombocytopenia was 3.1% and mucositis was 12.1%. The G3 acute mucositis was lower in SEQ group 16.7% than in SIB group 26.7, (p = 0.178), Also, in agree with Skidar et al., [ 31 ] who reported lower G3 mucositis in SEQ group 15.2% than that for SB group 21.2%. However, Grover et al., [ 37 ] reported higher G3 mucositis for SEQ group 45.1% vs. 40% for SIB group, may be due to high max dose to oral cavity in SEQ group 70.2 Gy vs. 68.8Gy for SIB group, also mean dose to esophagus was higher in SEQ group 23.4Gy than SIB group 26.1Gy. Regarding G3 acute dysphagia, it was lower for SEQ group 33% than SIB group 53%, (p = 0.032). Grover et al., [ 37 ] reported lower G3 dysphagia for SEQ-IMRT compared to SIB-IMRT 41.2%; vs. 72%, (p = 0.006) respectively. Sikdar et al., [ 31 ] also reported lower G3 dysphagia in SEQ 24.2% than SIB group 39.4%, (p = 0.029). As regard G3 acute dermatitis, it was 13% vs. 23%, (p = 0.155) in SEQ and SIB group respectively. Skidar et al.,[ 31 ] reported lower G3 dermatitis in SEQ group 18% than that for SIB 21%. However, Grover et al., [ 37 ] reported higher G3 dermatitis in SEQ group 13% vs. 10% for SIB group. While G2 xerostomia was higher for SEQ group than for SIB group 20% vs. 13.3%, respectively. Skidar et al., [ 31 ] reported higher G2 xerostomia in SEQ group 66.7% vs. 57.6% in SIB group. These high toxicities did not translate into significant weight loss with median weight loss 6 Kg vs. 6.4 Kg, for SEQ and SIB group respectively. Grover et al., [ 37 ] reported that mean weight-loss was 5.6 Kg vs. 5.04 kg in SEQ and SIB group respectively. No significant difference in the need for gastrostomy with 3.3% in SEQ group vs. 0.0% in SIB group. Vlacich et al., [ 34 ], result in higher gastrostomy tube placement in SIB group 67% vs. 62% in sequential group, may be due to higher grade3 dysphgia. Need for nasogastric tube (NGT) for feeding was higher for SEQ group 10% than SIB group 3.3%. Grover et al., [ 37 ] reported lower percentage for NGT in SEQ group 29.4% than SIB group 40%, may be due to higher grade3 dysphagia. Hospitalization was lower in SEQ group 33% than in SIB group 40%. Skidar et al., [ 31 ] reported higher hospitalization in SEQ group 45.5% vs. 42.4% for SIB group, may be due to higher percentage of dysphagia and need for nasogasric tube. As regard to G1-2 xerostomia was higher for SEQ group 36.7% vs. 30%, for SIB group. Mani et al., [ 33 ] reported higher late G1-2 xerostomia for SEQ group 82.3% vs. 76.5% in SIB group. Hoarseness of voice (laryngitis) was higher in SEQ group 33.3% vs. 26.7% in SIB group. Mani et al., [ 33 ] reported lower late G1-2 laryngitis in SEQ group 58.8% vs. 64.7% in SIB group. The other late toxicities observed in our study was G1-2 dermatitis which was lower in SEQ group 26.7% vs. 30% in SIB group. Mani et al., [ 33 ] reported higher late G1-2 dermatitis in SEQ group 35.3% vs. 29.4% in SIB group. Regarding compliance to treatment, the frequency of unplanned RT breaks were higher in the SEQ group than in the SIB group with mean (RT gap) was 5days (1–11 days) vs. 3.5 days (1–10 days) respectively, (p = 0.048). Grover et al., [ 37 ] found that patients in SEQIMRT arm had less treatment-compliance with mean treatment-interruption was 4.78 days (range, 1 to 8 days) compared to SIB-IMRT arm 2.8 days (range, 1 to 10 days), (p = 0.028). In the present study, according to the response after 2 months of finishing CCRT, SEQ group had lower OAR 56.7%, than in SIB group 76.7%. The CR was achieved in 26.7%. vs. 43% respectively. Mani et al., [ 33 ] reported CR after 3 months of CCRT was 76.5% vs. 64.7%, in SEQ and SIB arms, respectively. Partial response (PR) was 30% vs. 33.4% in SEQ and SIB group respectively. Grover et al., [ 37 ] found similar PR 26.73% in both groups. No statistically significant difference between different clinicopathological parameters with OAR and CR except with (PS2, T2, N2 and postcricoid site), in which OAR was higher for SIB group than for SEQ group (p = 0.030, 0.010, 0.043& 0.035) respectively. In our study, the median OS was not reached for whole patients and for each group with mean OS was 28 months for all patients and (26 months vs.29 months) for SEQ and SIB group respectively. For whole patients, 1-year OS was 98.3%, and at 2-years, OS was 61.5%, while for each group of the study, SEQ group had lower OS than SIB group at 1-year and 2-year of follow up 100.0% vs. 96.7% and 71.2% vs. 53.2% respectively, (p = 0.302). Also, Stromberger et al., [ 39 ] reported that the 3-year OS for SEQ versus SIB was 48% vs. 67% respectively. While Skidar et al., [ 31 ] reported higher OS for SEQ group at the end of 1-years 78.8% vs. 75.8% in the SIB group, also at 2year OS in SEQ group was higher 66.7% vs. 60.6% in SIB group. The median PFS was not reached for whole patients and for each group of the study with mean PFS was 24 months for the whole group and 23.5 months for each group. One-year PFS was 90% for all patients, also for SEQ and SIB groups. Also, at 2-year, PFS was still 84.6% for the whole patients and 82.4% vs. 86.4% for SEQ and SIB groups respectively. Tripathy et al., [ 32 ] reported mean PFS was 15.9 months vs. 26.9 months for CFRT and AHRT respectively. The median disease-free survival (DFS) also not reached with mean DFS was 31.9 months for whole patients, while it was lower for SEQ group 30 months vs. 32 months for SEQ group with one-year DFS was 95.2% for whole patients and at 2-years, it was 84.3%. While for each group, SEQ group had higher DFS than SIB group at 1-year 100.0% vs. 92.3% but at 2-year, DFS was higher for SIB group 92.3% vs. 71.4. Vlacich et al., [ 34 ] reported that at 4-years, DFS was lower in SEQ group 63% than SIB group 69%. Skinder et al., [ 31 ] reported that 1-year DFS was lower for SEQ group 63.6% than SIB group 69.7%. But at 2year, DFS for both groups was equal 60.6%. Manni et al., 2022 reported higher DFS at 18 months for SEQ group 70% vs. 68% for SIB group respectively. No statistical significant difference between different clinicopathological parameters and one year (OS, PFS or DFS) was found with (p > 0.05). The limitations of the study were that small number of participant patient in the study, single center study and the follow up time is not long enough. Conclusion Our study demonstrated that the SIB-IMRT arm achieved comparable treatment outcomes and acute toxicity rates, despite its reduced total treatment duration. This decrease in treatment time not only reduces costs but also alleviates the burden of busy radiation professionals. The SIB-IMRT is well-tolerated and results in improved treatment compliance for patients with head and neck cancer. Nevertheless, it is imperative to conduct a thorough evaluation of dysphagia and dietary procedures prior to implementing this approach. In terms of overall response and toxicity, there is no significant difference between SEQ-IMRT and SIB-IMRT. However, SIB-IMRT patients exhibit a superior overall response and complete response. Significant difference was only found between both groups as regard higher grade dysphagia for SIB-IMRT. OAR and complete response between both groups were significantly affected by PS, T stage, N stage and primary tumor site, with higher OAR in SIB-IMRT than in SEQ-IMRT for patients with PS2, T2, N2 and postcricoid region. Survival outcome including overall survival, progression free survival and disease free survival were better in SIB-IMRT than in SEQ-IMRT, but without statistical significance. Therefore, more studies in larger set of stage III-IVA SCC head and neck patients may possibly help in confirming the current study results and focused how to increase the survivors in that population. Superior dose painting when advanced techniques are available, such as intensity modulated arc therapy and volumetric modulated arc therapy can lead to more reduction in treatment time and more compliance of the patients with better saving of surrounding normal tissue and reduction of toxicity with SIB. Longer follow up duration for better evaluatin of survival out come and late toxicities. Declarations Statement of Ethics: The study was done after approval from the Ethics Committee of the Faculty of Medicine, Tanta University Hospitals (35092/12/21). An informed written consent was obtained from the patients. Conflicts of interest statement: The authors have no conflicts of interest to declare. Acknowledgement: Nil Financial support: Authors did not receive any external fund. Data Availability Statement: The data supporting the present findings are contained within the manuscript. Author Contribution All authors whose names appear on the submissionmade substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; and revised it critically for important intellectual content;approved the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. References Cohen N, Fedewa S, Chen AY. Epidemiology and Demographics of the Head and Neck Cancer Population. Oral Maxillofac Surg Clin North Am. 2018;30:381-95.https://doi.org/10.1016/j.coms.2018.06.001 Saba NF, Pamulapati S, Patel B, et al. Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer. Cancers (Basel). 2023;15:43-67.https://doi.org/10.3390/cancers15071959 Ferrari D, Ghi MG, Franzese C, et al. The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality. Front Oncol. 2020;10:7-79.https://doi.org/10.3389/fonc.2020.00007 Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016;91:386-96.https://doi.org/10.1016/j.mayocp.2015.12.017 Nissi L, Suilamo S, Kytö E, et al. Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume. Clin Transl Radiat Oncol. 2021;27:139-46.https://doi.org/10.1016/j.ctro.2021.01.013 Pagh A, Grau C, Overgaard J. Failure pattern and salvage treatment after radical treatment of head and neck cancer. Acta Oncologica. 2016;55:625-32 Leclerc M, Maingon P, Hamoir M, et al. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach. Radiother Oncol. 2013;106:33-40.https://doi.org/10.1016/j.radonc.2013.03.002 Atwell D, Elks J, Cahill K, et al. A Review of Modern Radiation Therapy Dose Escalation in Locally Advanced Head and Neck Cancer. Clin Oncol (R Coll Radiol). 2020;32:330-41.https://doi.org/10.1016/j.clon.2019.12.004 Hsieh CH, Shueng PW, Wang LY, et al. Single-Institute Clinical Experiences Using Whole-Field Simultaneous Integrated Boost (SIB) Intensity-Modulated Radiotherapy (IMRT) and Sequential IMRT in Postoperative Patients With Oral Cavity Cancer (OCC). Cancer Control. 2020;27:10-73.https://doi.org/10.1177/1073274820904702 Mireștean CC, Iancu RI, Iancu DPT. Simultaneous Integrated Boost (SIB) vs. Sequential Boost in Head and Neck Cancer (HNC) Radiotherapy: A Radiomics-Based Decision Proof of Concept. J Clin Med. 2023;12:43-67.https://doi.org/10.3390/jcm12062413 Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual: Springer; 2017. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55 Di Fiore F, Lecleire S, Rigal O, et al. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol. 2006;12:85-90.https://doi.org/10.3748/wjg.v12.i26.4185 Hodapp N. [The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)]. Strahlenther Onkol. 2012;188:97-9.https://doi.org/10.1007/s00066-011-0015-x Grégoire V, Evans M, Le QT, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018;126:3-24.https://doi.org/10.1016/j.radonc.2017.10.016 Brodin NP, Kabarriti R, Garg MK, et al. Systematic Review of Normal Tissue Complication Models Relevant to Standard Fractionation Radiation Therapy of the Head and Neck Region Published After the QUANTEC Reports. Int J Radiat Oncol Biol Phys. 2018;100:391-9.https://doi.org/10.1016/j.ijrobp.2017.09.041 Tai DT, Oanh LT, Phuong PH, et al. Dosimetric and radiobiological comparison in head-and-neck radiotherapy using JO-IMRT and 3D-CRT. Saudi J Biol Sci. 2022;29:10-33.https://doi.org/10.1016/j.sjbs.2022.103336 Chakrabarti D, Verma M, Resu AV, et al. Unscheduled Treatment Gaps in Head and Neck Cancer Radiotherapy. Bengal J Cancer. 2022;2:25-30 Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021;112:90-2.https://doi.org/10.1016/j.ad.2019.05.009 Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:41-6.https://doi.org/10.1016/0360-3016(95)00060-c Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:28-47.https://doi.org/10.1016/j.ejca.2008.10.026 Prinja S, Gupta N, Verma R. Censoring in clinical trials: review of survival analysis techniques. Indian J Community Med. 2010;35:17-21.https://doi.org/10.4103/0970-0218.66859 Kilickap S, Demirci U, Karadurmus N, et al. Endpoints in oncology clinical trials. J buon. 2018;23:1-6 Wilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol. 2015;16:32-42.https://doi.org/10.1016/s1470-2045(14)70375-4 Habibzadeh F. Statistical Data Editing in Scientific Articles. J Korean Med Sci. 2017;32:1072-6.https://doi.org/10.3346/jkms.2017.32.7.1072 Najmi A, Sadasivam B, Ray A. How to choose and interpret a statistical test? An update for budding researchers. J Family Med Prim Care. 2021;10:2763-7.https://doi.org/10.4103/jfmpc.jfmpc_433_21 Guglielmetti LC, Faber-Castell F, Fink L, et al. Statistics decrypted-a comprehensive review and smartphone-assisted five-step approach for good statistical practice. Langenbecks Arch Surg. 2022;407:529-40.https://doi.org/10.1007/s00423-021-02360-0 Hess AS, Hess JR. Understanding tests of the association of categorical variables: the Pearson chi-square test and Fisher's exact test. Transfusion. 2017;57:877-9.https://doi.org/10.1111/trf.14057 Andrade C. Survival Analysis, Kaplan-Meier Curves, and Cox Regression: Basic Concepts. Indian J Psychol Med. 2023;45:434-5.https://doi.org/10.1177/02537176231176986 Eom KY. Hypofractionated radiation therapy for head and neck cancers in the era of intensity-modulated radiation therapy. Radiat Oncol J. 2024;42:1-3.https://doi.org/10.3857/roj.2024.00178 SIKDAR D, Joseph DM, Sharma N, et al. A Prospective Randomized Study of Sequential Boost vs Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy in Locally Advanced Head and Neck Cancer. Res Sq. 2024:43-67 Tripathy A, Muzumder S, Srikantia N, et al. A comparison of conventional and accelerated hypofractionated radiotherapy in definitive chemoradiation for locally advanced head and neck carcinoma: a retrospective cohort study. Radiat Oncol J. 2023;41:248-57.https://doi.org/10.3857/roj.2023.00248 Mani N, Aggarwal SK, Kumar I, et al. A prospective randomized comparison of simultaneous integrated boost with sequential boost intensity-modulated radiotherapy in locally advanced head and neck cancer. J Cancer Res Ther. 2022;18:455-9.https://doi.org/10.4103/jcrt.jcrt_1358_22 Vlacich G, Stavas MJ, Pendyala P, et al. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer. Radiat Oncol. 2017;12:13-76.https://doi.org/10.1186/s13014-016-0756-x Rakesh A, Goyal J, Soni S, et al. A Comparative Study of Planning and Dosimetry in Locally Advanced Head-And-Neck Cancer: Sequential versus Simultaneous Integrated Boost Methods in Intensity-Modulated Radiotherapy. J Radiat Cancer Res. 2022;13:41-7 Rakesh A, Goyal J, Soni S, et al. A Comparative Study of Planning and Dosimetry in Locally Advanced Head-And-Neck Cancer: Sequential versus Simultaneous Integrated Boost Methods in Intensity-Modulated Radiotherapy. J Radiat Cancer Res. 2022;13:41-7.https://doi.org/10.4103/jrcr.jrcr_46_21 Grover A, Soni TP, Patni N, et al. A randomized prospective study comparing acute toxicity, compliance and objective response rate between simultaneous integrated boost and sequential intensity-modulated radiotherapy for locally advanced head and neck cancer. Radiat Oncol J. 2021;39:15-23.https://doi.org/10.3857/roj.2020.01018 Zhang L, Jiang N, Shi Y, et al. Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis. Sci Rep. 2015;5:10-79.https://doi.org/10.1038/srep10798 Stromberger C, Stsefanenka A, Kalinauskaite G, et al. Simultaneous integrated boost or sequential boost (chemo) radiation for locally advanced head and neck cancer: the same is the same? Int J Radiat Oncol Biol Phys. 2020;108:849-69 Tables Table 1: Clinicopathological parameters and concurrent chemotherapy with radiotherapy for both groups All patients (n=60) Group A (SEQ-IMRT) (n=30) Group B (SIB-IMRT) (n=30 ) P Clinicopathological parameters Age (yrs.) = 62 32 (53.3%) 18 (60%) 14 (46.7%) Age (yrs.) 61.5±8.44 62.4 ± 8.35 60.5 ± 8.58 0.380 sex Male 49 (81.7%) 23 (76.7%) 26 (86.7%) 0.317 Female 11 (18.3%) 7 (23.3%) 4 (13.3%) Smoking Never smoker 14 (23.3%) 7 (23.3%) 7 (23.340%) 0.840 Light smoker 22 (36.7%) 10 (33.3%) 12 (36.7%) Heavy smoker 24 (40.0%) 13 (43.3%) 11 PS (performance status) PS0 12 (20.0%) 5 (16.7%) 7 (23.3%) 0.784 PS1 26 (43.3%) 14 (46.7%) 12 (40%) PS2 22 (36.7%) 11 (36.7%) 11 (36.7%) Co-morbidities DM 12 (20.0%) 9 (30.0%) 3 (10.0%) 0.053 HTN 11 (18.3%) 7 (23.3%) 4 (13.3%) 0.317 Primary tumor site Oral cavity Larynx 7 (11.7%) 5 (16.7%) 2 (6.7%) 0.372 40 (66.7%) 20 (66.7%) 20 (66.7%) Hypopharynx 13 (21.7%) 5 (16.7%) 8 (26.7%) Oral tongue 7 (11.7%) 5 (16.7%) 2 (6.7%) 0.228 Supra glottis region 27 (45.0%) 16 (53.3%) 11 (36.7%) 0.194 Glottic region 13 (21.7%) 4 (13.3%) 9 (30.0%) 0.117 Pyriform sinus 5 (8.3%) 2 (6.7%) 3 (10.0%) 0.640 Postcricoid region 8 (13.4%) 3 (10.0%) 5 (16.7%) 0.448 T stage T2 15 (25.0%) 8 (26.7%) 7 (23.3%) 0.949 T3 27 (45.0%) 13 (43.3%) 14 (46.7%) T4a 18 (30.0%) 9 (30.0%) 9 (30.0%) N stage N0 16 (26.7%) 7 (23.3%) 9 (30.0%) 0.324 N1 3 (5.0%) 3 (10%) 0 (0.0%) N2 41 (68.3%) 20 (66.7%) 21 (70%) Stage III 12 (20.0%) 6 (20.0%) 6 (20.0%) 1.000 IVA 48 (80.0%) 24 (80.0%) 24 (80.0%) Grade G1 7 (11.7%) 3 (10.0%) 4 (13.3%) 0.918 G2 35 (58.3%) 18 (60.0%) 17 (56.7%) G3 18 (30.0%) 9 (30.0%) 4 (30.0%) Type of concurrent chemotherapy Cisplatin 51 (85.0%) 25 (83.3%) 26 (86.7%) 0.718 Carboplatin 9 (15.0%) 5 (16.7%) 4 (13.3%) Data are presented as mean ± SD or frequency (%). PS: performance status. SEQ-MRT: Sequential IMRT. SIB-IMRT: Intensity-modulated radiotherapy using simultaneous integrated boost. Table 2: Dosimetric parameters of planning target volume high risk (PTV HR), planning target volume intermediate risk (PTV IR), planning target volume low risk (PTV LR) and organ at risk (OARs) for both groups Group A (SEQ-IMRT) (n=30) Group B (SIB-IMRT) (n=30 ) P PTV HR D max (Gy) 72.59 ± 3.33 67.12 ± 2.60 0.013* D min (Gy) 65.73 ± 1.80 62.89 ± 1.67 0.003* D mean (Gy) 68.95 ± 2.13 64.6 ± 1.70 0.185 D 95% (Gy) 67.41 ± 2.06 65.47 ± 1.74 <0.001* Volume (cm3) 89.4 ± 55.03 56.7 ± 33.81 0.012* HI 0.23 ± 0.18 0.08 ± 0.06 <0.001* CI 0.82 ± 0.13 0.95 ± 0.06 <0.001* PTV IR D max (Gy) 63.3 ± 3.97 62.7 ± 2.76 0.250 D min (Gy) 56.46 ± 1.69 57.54 ± 1.72 <0.001* D mean (Gy) 59.1 ± 2.85 58.8 ± 2.63 0.462 D 95% (Gy) 58.5 ± 2.97 58.86 ± 2.82 0.381 Volume (cm3) 393.1 ± 165.89 434.3 ± 164.09 0.333 HI 0.24 ± 0.14 0.14 ± 0.11 0.005* CI 0.81 ± 0.14 0.95 ± 0.05 <0.001* PTV LR D max (Gy) 58.46 ± 4.01 57.51 ± 4.52 0.127 D min (Gy) 52.86 ± 1.65 53.48 ± 1.86 0.013* D mean (Gy) 56.50 ± 4.59 56.17 ± 2.67 0.553 D 95% (Gy) 54.77 ± 1.92 54.99 ± 2.73 0.470 Volume (cm3) 255.3 ± 198.97 341.9 ± 225.86 0.093 HI 0.24 ± 0.16 0.14 ± 0.11 0.012* CI 0.81 ± 0.12 0.93 ± 0.06 <0.001* Organ at risk (OARs) Esophagus mean dose 28.2 ± 8.59 29.9 ± 6.77 0.391 Oral cavity mean dose 29.2 ± 6.74 26.3 ± 8.02 0.137 Spinal cord Dmax 38.4 ± 4.09 39.7 ± 6.11 0.338 Right parotid mean dose 22.1 ± 3.22 21.6 ± 4.26 0.676 Left parotid mean dose 21.58 ± 4.02 21.7 ± 4.31 0.897 Data presents as mean ± SD or frequency (%). SEQ-MRT: Sequential IMRT. SIB-IMRT: Intensity-modulated radiotherapy using simultaneous integrated boost.* significant as P-value ≤ 0.05. Table 3: Grades of acute mucositis, grades of acute dysphagia, grades of acute dermatitis and grades of acute xerostomia during CCRT for both groups Group A (SEQ-MRT) (n=30) Group B (SIB-IMRT) (n=30 ) P Grades of acute mucositis W2 G0 22 (73.3 %) 20 (66.7 %) 0.886 G1 7 (23.3 %) 9 (30 %) G2 1 (3.3 %) 1 (3.3 %) W4 G0 0 (0.00%) 0 (0.00%) 0.390 G1 14 (46.6%) 10 (33.3%) G2 14 (46.7%) 15 (50.0%) G3 2 (6.7%) 5 (16.7%) W6 G0 0 (0.00%) 0 (0.00%) 0.178 G1 7 (23.3%) 2 (6.6%) G2 18 (60.0%) 20 (66.7%) G3 5 (16.7%) 8 (26.7%) Grades of acute dysphagia W2 G0 20 (66.7%) 13 (43.3%) 0.146 G1 9 (30.0%) 16 (53.4%) G2 1 (3.3%) 1 (3.3%) W4 G0 0 (0.0%) 0 (0.0%) 0.024* G1 17 (56.7%) 7 (23.3%) G2 9 (30.0%) 13 (43.3%) G3 4 (13.3%) 10 (33.3%) W6 G0 0 (0.00%) 0 (0.00%) 0.032* G1 10 (33.3%) 2 (6.7%) G2 10 (33.4%) 12 (40.0%) G3 10 (33.3%) 16 (53.3%) Grades of acute dermatitis W2 G0 21 (70%) 18 (60%) 0.417 G1 9 (30%) 12 (40%) W4 G0 11 (36.7%) 4 (13.3%) 0.113 G1 12 (40.0%) 16 (53.3%) G2 7 (23.3%) 10 (33.3%) W6 G0 0 (0.00%) 0 (0.00%) 0.155 G1 14 (46.7%) 7 (23.3%) G2 12 (40.0%) 16 (53.3%) G3 4 (13.3%) 7 (23.3%) Grades of acute xerostomia W2 G0 28 (93.3 %) 26 (86.7%) 0.671 G1 2 (6.7 %) 4 (13.3%) W4 G0 16 (53.3 %) 17 (56.7%) 0.798 G1 14 (46.7%) 12 (40.0%) G2 0 (0.0%) 1 (3.3%) W6 G0 7 (23.3%) 9 (30.0%) 0.726 G1 17 (56.7%) 16 (53.3%) G2 6 (20.0%) 4 (13.3 %) G3 0 (0.0 %) 1 (3.3%) Data presents as mean ± SD or frequency (%), SEQ-MRT: Sequential IMRT. SIB-IMRT: Intensity-modulated radiotherapy using simultaneous integrated boost.* significant as P-value ≤ 0.05. Table 4: Body mass index after CCRT, compliance to treatment during CCRT, post treatment acute toxicity and late toxicity for both groups Group A (SEQIMRT) (n=30) Group B (SIB- IMRT) (n=30 ) P Pre BMI (Kg/m2) < 18.5 2 (6.7%) 1 (3.3%) 1.000 18.5 to 24.9 28 (93.3%) 28 (93.3%) 25 to 29.9 0 (0.0%) 1 (3.3%) Post BMI (Kg/m2) < 18.5 5 (16.7%) 7 (23.3%) 0.537 18.5 to 24.9 25 (83.3%) 22 (73.3%) 25 to 29.9 0 (0.00%) 1 (3.3%) Weight Loss (Kg) 6.23 ± 2.01 5.5 ± 2.43 0.550 Gastrostomy 1 (3.3%) 0 (0.0%) 1.000 Nasogastric tube 3 (10.0%) 1 (3.3%) 0.612 Hospitalization (RTH toxicity) 10 (33.3%) 12 (40%) 0.592 Inturruption (days) 5.0 ± 4.07 3.5 ± 3.04 0.509 Post treatment acute toxicity Acute Dermatitis G0 16 (23.3%) 13 (43.3%) 0.684 G1 11 (36.7%) 12 (40.0%) G2 3 (10.0%) 5 (16.7%) Acute mucositis G0 16 ( 53.3%) 19 (63.3%) 0.649 G1 10 (33.3%) 9 (30.0%) G2 4 (13.3%) 2 (6.7%) Acute dysphagia G0 19 (63.3%) 15 (50%) 0.444 G1 9 (30.0%) 10 (33.3%) G2 2 (6.7%) 5 (16.7%) Acute xerostomia G0 8 (26.7%) 5 (16.7%) 0.093 G1 14 (46.7%) 22 (73.3%) G2 8 (26.7%) 3 (10.0%) Neuropathy G0 19 (63.3%) 18 (60.0%) 1.000 G1 8 (26.7%) 9 (30.0%) G2 3 (10.0%) 2 (6.7%) G3 0 (0.0%) 1 (3.3%) Post treatment late toxicity Late dermatitis G0 22 (73.3%) 21 (70.0%) 1.000 G1 6 (20.0%) 7 (23.3%) G2 2 (6.7%) 2 (6.7%) Late xerostomia G0 19 (63.3%) 21 (70.0%) 1.000 G1 8 (26.7%) 7 (23.3%) G2 3 (10%) 2 (6.7%) Laryngitis (hoarseness of voice) G0 17 (56.7%) 22 (73.3%) 0.440 G1 9 (30.0%) 6 (20.0%) G2 4 (13.3%) 2 (6.7%) Data presents as mean ± SD or frequency (%). BMI: body mass index, SEQ-MRT: Sequential IMRT. SIB-IMRT: Intensity-modulated radiotherapy using simultaneous integrated boost. Table 5: Response to concurrent chemo radiotherapy for both groups, according to age, sex, performance status and smoking for both groups All patients (n=60) Group A(SEQ-IMRT) (n=30) Group B (SIB- IMRT) (n=30 ) p CR 21 (35.0%) 8 (26.7%) 13 (43.3%) 0.384 PR 19 (31.7%) 9 (30.0%) 10 (33.3%) SD 17 (28.3%) 11 (36.7%) 6 (20.0%) PD 3 (5%) 2 (6.7%) 1 (3.3%) Responsive (OAR) (CR+PR) 40 (66.7%) 17 (56.7%) 23 (76.7%) 0.1000 Non responsive (SD+PD) 20 (33.3%) 13 (43.3%) 7 (23.3%) Age =62 Y SEQ (n=12) SIB (n=16) p SEQ (n=18) SIB (n=14) p CR 6 (50.0%) 8 (50.0%) 0.627 2 (11.1%) 5 (35.7%) 0.408 PR 3 (5.0%) 6 (37.5%) 6 (33.3%) 4 (28.6%) SD 3 (25.0%) 2 (12.5%) 8 (44.0%) 4 (28.6%) PD 0 (0.0%) 0 (0.0%) 2 (11.1%) 1 (7.1%) Responsive (OAR) (CR+PR) 9 (75.0%) 14 (87.5%) 0.393 8 (44.0%) 9 (64.3%) 0.265 Non responsive (SD+PD) 3 (5.0%) 2 (12.5%) 10 (55.6%) 5 (35.7%) Male Female SEQ (n=23) SIB (n=26) p SEQ (n=7) SIB (n=4) p CR 7 (30.4%) 11 (42.3%) 0.656 1 (14.3%) 2 50.0 0.231 PR 6 (26.1%) 8 (30.8%) 3 (42.9%) 2 50.0 SD 8 (34.8%) 6 (23.1%) 3 (42.9%) 0 0.0 PD 2 (8.7%) 1 (3.8%) 0 (0.0%) 0 0.0 Responsive (OAR) (CR+PR) 13 (56.5%) 19 (73.1%) 0.224 4 (57.1%) 4 100.0 0.125 Non responsive (SD+PD) 10 (43.5%) 7 (26.9%) 3 (42.9%) 0 0.0 PS 0 PS 1 PS 2 SEQ (n=5) SIB (n=7) p SEQ (n=14) SIB (n=12) p SEQ (n=11) SIB (n=11) P CR 3 (60.0%) 6 (85.7%) 0.310 4 (28.6%) 4 (33.3%) 0.656 1 (9.1%) 3 (27.3%) 0.132 PR 2 (40.0%) 1 (14.3%) 6 (42.9%) 5 (41.7%) 1 (9.1%) 4 (36.4%) SD 0 (0.0%) 0 (0.0%) 4 (28.6%) 2 (16.7%) 7 (63.6%) 4 (36.4%) PD 0 (0.0%) 0 (0.0%) 0 (0.0%) c1 (8.3%) 2 (18.2%) 0 (0.0%) Responsive (OAR) (CR+PR) 5 (100.0%) 7 (100.0%) - 10 (71.4%) 9 (75.0%) 0.838 2 (18.2%) 7 (63.6%) 0.030* Non responsive (SD+PD) 0 (0.0%) 0 (0.0%) 4 (28.6%) 3 (25.0%) 9 (81.8%) 4 (36.4%) Response state Non smoker Light smoker Heavy smoker SEQ (n=7) SIB (n=7) p SEQ (n=10) SIB (n=12) p SEQ (n=13) SIB (n=11) P CR 1 (14.3%) 4 (28.6%) 0.112 5 (50.0%) 7 (58.3%) 0.263 2 (15.4%) 2 (18.2%) 0.605 PR 3 (42.9%) 2 (28.6%) 4 (40.0%) 5 (41.7%) 2 (15.4%) 3 (27.3%) SD 3 (42.9%) 0 (0.0%) 1 (10.0%) 0 (0.0%) 7 (53.8%) 6 (54.5%) PD 0 (0.0%) 1 (14.3%) 0 (0.0%) 0 (0.0%) 2 (15.4%) 0 (0.0%) Responsive (OAR) (CR+PR) 4 (57.1%) 6 (85.7%) 0.237 9 (90.0%) 12 (100.0%) 0.262 4 (30.8%) 5 (45.5%) 0.459 Non responsive (SD+PD) 3 (42.9%) 1 (14.3%) 1 (10.0%) 0 (0.0%) 9 (69.2%) 6 (54.5%) Data presents as frequency (%).CR: complete response, PR: partial response, SD: stationary disease, PD: progressive disease, OAR: overall response. SEQ: Sequential IMRT. SIB: Intensity-modulated radiotherapy using simultaneous integrated boost.* Significant as P-value ≤ 0.05. Table 6: Response to concurrent chemoradiotherapy according to primary tumor site, supraglottic sub site, glottic sub site, pyriform sinus subsite and postcricoid sub site for both groups primary tumor site Oral cavity (oral tongue) Larynx Hypopharynx SEQ (n=5) SIB (n=2) p SEQ (n=20) SIB (n=20) p SEQ (n=5) SIB (n=8) P CR 0 (0.0%) 0 (0.0%) 0.792 8 (40.0%) 9 (45.0%) 0.785 0 (0.0%) 4 (50.0%) 0.121 PR 2 (40.0%) 1 (50.0%) 5 (25.0%) 6 (30.0%) 2 (40.0%) 3 (37.5%) SD 2 (40.0%) 1 (50.0%) 7 (35.0%) 5 (25.0%) 2 (40.0%) 0 (0.0%) PD 1 (20.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (20.0%) 1 (12.5%) Responsive (OAR)(CR+PR) 2 (40.0%) 1 (50.0%) 0.809 13 (65.0%) 15 (75.0%) 0.490 2 (40.0%) 7 (87.5%) 0.071 Non responsive (SD+PD) 3 (60.0%) 1 (50.0%) 7 (35.0%) 5 (25.0%) 3 (60.0%) 1 (12.5%) Supra glottis region SEQ(n=16) SIB (n=11) p CR 5 (31.3%) 5 (45.5%) 0.743 PR 5 (31.3%) 3 (27.3%) SD 6 (37.5%) 3 (27.3%) PD 0 (0.0%) 0 (0.0%) Responsive (OAR) (CR+PR) 10 (62.5%) 8 (72.7%) 0.580 Non responsive (SD+PD) 6 (37.5%) 3 (27.3%) Glottic region SEQ(n=4) SIB(n=9) P CR 3 (75.0%) 4 (44.4%) 0.283 PR 0 (0.0%) 3 (33.3%) SD 1 (25.0%) 2 (22.2%) PD 0 (0.0%) 0 (0.0%) Responsive (OAR)(CR+PR) 3 (75.0%) 7 (77.8%) 0.913 Non responsive (SD+PD) 1 (25.0%) 2 (22.2%) Pyriform sinus region SEQ(n=2) SIB(n=3) p CR 0 (0.0%) 1 (33.3%) 0.569 PR 1 (50.0%) 1 (33.3%) SD 1 (50.0%) 1 (33.3%) PD 0 (0.0%) 0 (0.0%) Responsive (OAR)(CR+PR) 1 (50.0%) 2 (66.7%) 0.709 Non responsive (SD+PD) 1 (50.0%) 1 (33.3%) Post cricoid region SEQ(n=3) SIB(n=5) p CR 0 (0.0%) 3 (60.0%) 0.076 PR 1 (33.3%) 2 (40.0%) SD 2 (66.7%) 0 (0.0%) PD 0 (0.0%) 0 (0.0%) Responsive (OAR)(CR+PR) 1 (33.3%) 5 (100.0%) 0.035* Non responsive (SD+PD) 2 (66.7%) 0 (0.0%) Data presents as mean ± SD or frequency (%).SEQ: Sequential IMRT. SIB: Intensity-modulated radiotherapy using simultaneous integrated boost. CR: Complete response, PR: Partial response, SD: Stationary disease, PD: Progressive disease, OAR: Overall response, *: significant as P value ≤ 0.05. Table 7: Response to concurrent chemoradiotherapy according to grade, T stage, N stage, stage, type of concurrent chemotherapy and gap of interruption for both groups Grade Response state G1 G2 G3 SEQ (n=3) SIB (n=4) p SEQ (n=18) SIB (n=17) p SEQ (n=9) SIB (n=9) P CR 3 (100.0%) 4 (100.0%) - 4 (22.2%) 7 (41.2%) 0.344 1 (11.1%) 2 (22.2%) 0.381 PR 0 (0.0%) 0 (0.0%) 9 (50.0%) 8 (47.1%) 0 (0.0%) 2 (22.2%) SD 0 (0.0%) 0 (0.0%) 5 (27.8%) 2 (11.8%) 6 (66.7%) 4 (44.4%) PD 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (22.2%) 1 (11.1%) Responsive (OAR) (CR+PR) 3 (100.0%) 4 (100.0%) - 13 (72.2%) 15 (88.2%) 0.237 1 (11.1%) 4 (44.4%) 0.114 Non responsive (SD+PD) 0 (0.0%) 0 (0.0%) 5 (27.8%) 2 (11.8%) 8 (88.9%) 5 (55.6%) T stage T2 T3 T4a SEQ (n=8) SIB (n=7) p SEQ (n=13) SIB (n=14) p SEQ (n=9) SIB (n=9) P CR 2 (25.0%) 6 (85.7%) 0.073 4 (30.8%) 5 (35.7%) 0.756 2 (22.2%) 2 (22.2%) 0.637 PR 1 (12.5%) 1 (14.3%) 5 (38.5%) 4 (28.6%) 3 (33.3 %) 5 (55.6 %) SD 4 (50.0%) 0 (0.0%) 4 (30.8%) 4 (28.6%) 3 (33.3 %) 2 (22.2 %) PD 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (7.1%) 1 (11.1 %) 0 (0.0 %) Responsive (OAR) (CR+PR) 3 (37.5%) 7 (100.0%) 0.010* 9 (69.2%) 9 (64.3%) 0.785 5 (55.6%) 7 (76.7 %) 0.317 Non responsive (SD+PD) 5 (62.5%) 0 (0.0%) 4 (30.8%) 5 (35.7%) 4 (43.3%) 2 (23.3%) N stage NO N1 N2 SEQ (n=7) SIB (n=9) p SEQ (n=3) SIB (n=0) P SEQ (n=20) SIB (n=21) P CR 2 (28.6%) 6 (66.7%) 0.131 2 (66.7%) 0 (0.0%) - 4 (20.0 %) 7 (33.3 %) 0.241 PR 5 (71.4%) 3 (33.3%) 1 (33.3%) 0 (0.0%) 3 (15.0%) 7 (33.3 %) SD 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 11 (55.0%) 6 (28.6 %) PD 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (10.0%) 1 (4.8 %) Responsive (OAR) (CR+PR) 7 (%)100.0 9 (100.0%) - 3 (100.0%) 0 (0.0%) - 7 (35.0 %) 14 (66.7 %) 0.043* Non responsive (SD+PD) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 13 65.0 7 (33.3 %) stage for both groups Stage III Stage IV SEQ (n=6) SIB (n=4) p SEQ (n=24) SIB (n=24) p CR 4 (66.7%) 4 (66.7%) 1.00 4 (16.7%) 9 (37.5%) 0.285 PR 2 (33.3%) 2 (33.3%) 7 (29.2%) 8 (33.3%) SD 0 (0.0%) 0 (0.0%) 11 (45.8%) 6 (25.0%) `PD 0 (0.0%) 0 (0.0%) 2 (8.3%) 1 (4.2%) Responsive (OAR)(CR+PR) 6 (100.0%) 6 (100.0%) - 11 (45.8%) 17 (70.8%) 0.079 Non responsive (SD+PD) 0 (0.0%) 0 (0.0%) 13 (54.2%) 7 (29.2%) Type of concurrent chemotherapy Cisplatin Carboplatin CR 8 (32.0%) 13 (50.0%) 0.136 0 (0.0%) 0 (0.0%) 0.638 PR 7 (28.0%) 9 (34.6%) 2 (40.0%) 1 (25.0%) SD 10 (40.0%) 4 (15.4%) 1 (20.0%) 2 (50.0%) PD 0 (0.0%) 0 (0.0%) 2 (40.0%) 1 (25.0%) Responsive (OAR)(CR+PR) 15 (60.0%) 22 (84.6%) 0.049 2 (40.0%) 1 (25.0%) 0.635 Non responsive (SD+PD) 10 (40.0%) 4 (15.4%) 3 (60.0%) 3 (75.0%) Gap of interruption No gap Gap >=1 day SEQ (n=14) SIB (n=20) p SEQ(n=16) SIB(n=10) p CR 6 (42.9%) 9 (45.0%) 0.991 2 (12.5%) 4 (40.0%) 0.315 PR 5 (35.7%) 7 (35.0%) 4 (25.0%) 3 (30.0) SD 3 (21.4%) 4 (20.0%) 8 (50.0%) 2 (20.0%) PD 0 (0.0%) 0 (0.0%) 2 (12.5%) 1 (10.0%) Responsive (OAR)(CR+PR) 11 (78.6%) 16 (80.0%) 0.919 6 (37.5%) 7 (70.0%) 0.107 Non responsive (SD+PD) 3 (21.4%) 4 (20.0%) 10 (62.5%) 3 (30.0%) Data presents as mean ± SD or frequency (%).SEQ: Sequential IMRT. SIB: Intensity-modulated radiotherapy using simultaneous integrated boost. CR: Complete response, PR: Partial response, SD: Stationary disease, PD: Progressive disease, OAR: Overall response, *: significant as P value ≤ 0.05. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 15 Nov, 2025 Read the published version in Medical Oncology → Version 1 posted Editorial decision: Revision requested 26 Aug, 2025 Reviews received at journal 18 Aug, 2025 Reviews received at journal 17 Aug, 2025 Reviewers agreed at journal 14 Aug, 2025 Reviews received at journal 14 Aug, 2025 Reviewers agreed at journal 11 Aug, 2025 Reviewers agreed at journal 11 Aug, 2025 Reviewers invited by journal 10 Aug, 2025 Editor assigned by journal 08 Jul, 2025 Submission checks completed at journal 08 Jul, 2025 First submitted to journal 03 Jul, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7041401","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":501505825,"identity":"3ca32d75-c8df-4add-9ac5-bc4649608041","order_by":0,"name":"Sahar Samy Abo El-Atta","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABP0lEQVRIiWNgGAWjYFACHhSeBRAzNj74YGADZhwgQosEEDM3G86oSANpaSBWC3ubNM+Zw2AuNi3y7WcPfq74YxdtcID52IMfFRJy8hGJbdK8beft1rYfBtpSYxONpsXgTF6y5Nm25NwNB9jSDXvOSBgb3khstpzbdjt525lEoJZjabkNaFoYcgwkGxuYgVp4zKQZ2yQSN85IbLzxFqjF7ABQC2PDYXQt8v1vjH82/KlH0dIgwdt2Ltns/EOsWhhu5JhJNrAdRmiZL5HYJMlz5oCd2Q3sthjceGNm2dh2PHfmYbY0SZBfDHgeggI5OcHsBtCWBEy/yPfnGN9s+FOd23e8+ZjEjwobOfn29IfAqLSzNzsPYtTYYDgMBhQOw+y9kACmE8EqE3AoB1sHM0u+/wCYtsejeBSMglEwCkYWAAAwm4c8XnQrvAAAAABJRU5ErkJggg==","orcid":"","institution":"Tanta University","correspondingAuthor":true,"prefix":"","firstName":"Sahar","middleName":"Samy Abo","lastName":"El-Atta","suffix":""},{"id":501505826,"identity":"1510e460-f231-46fd-9883-9e1d0f6f33d3","order_by":1,"name":"Alaa Mohamed Maria","email":"","orcid":"","institution":"Tanta University","correspondingAuthor":false,"prefix":"","firstName":"Alaa","middleName":"Mohamed","lastName":"Maria","suffix":""},{"id":501505827,"identity":"3fa944c8-ddbe-413d-b705-802223165227","order_by":2,"name":"Lamiss Mohammed Abd-Elaziz","email":"","orcid":"","institution":"Tanta University","correspondingAuthor":false,"prefix":"","firstName":"Lamiss","middleName":"Mohammed","lastName":"Abd-Elaziz","suffix":""},{"id":501505829,"identity":"b6b5c8a2-6233-4ae7-815b-876a00665313","order_by":3,"name":"Asmaa Mohamed El-Kady","email":"","orcid":"","institution":"Tanta University","correspondingAuthor":false,"prefix":"","firstName":"Asmaa","middleName":"Mohamed","lastName":"El-Kady","suffix":""},{"id":501505831,"identity":"7411c299-b680-4ce4-9545-9bf00f9f75b4","order_by":4,"name":"Emad Mohammed Shehata","email":"","orcid":"","institution":"Tanta University","correspondingAuthor":false,"prefix":"","firstName":"Emad","middleName":"Mohammed","lastName":"Shehata","suffix":""}],"badges":[],"createdAt":"2025-07-03 21:23:04","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7041401/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7041401/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s12032-025-03110-8","type":"published","date":"2025-11-15T15:56:59+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":89378037,"identity":"3856fa4d-354d-4eb3-bb3b-930abf11653f","added_by":"auto","created_at":"2025-08-19 11:29:09","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":892580,"visible":true,"origin":"","legend":"\u003cp\u003eLegend not included with this version.\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7041401/v1/7611f4729bf66a86b86fe265.png"},{"id":89378036,"identity":"d1408792-257e-442f-8651-ade9e08733d4","added_by":"auto","created_at":"2025-08-19 11:29:09","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":847343,"visible":true,"origin":"","legend":"\u003cp\u003eLegend not included with this version.\u003c/p\u003e","description":"","filename":"floatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-7041401/v1/cfa4aecb3185fe6f39319be1.png"},{"id":89379281,"identity":"12efbbb1-e38c-410f-9856-73e168fb9596","added_by":"auto","created_at":"2025-08-19 11:37:09","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":128783,"visible":true,"origin":"","legend":"\u003cp\u003eLegend not included with this version.\u003c/p\u003e","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-7041401/v1/1412a579be6369a942e14a6e.png"},{"id":89378046,"identity":"f3296d8f-9e17-4d96-b54e-94eec7c6bb31","added_by":"auto","created_at":"2025-08-19 11:29:09","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":164173,"visible":true,"origin":"","legend":"\u003cp\u003eLegend not included with this version.\u003c/p\u003e","description":"","filename":"floatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-7041401/v1/f5391f5bce2382fdbf5d7b66.png"},{"id":96105193,"identity":"1e27ebbd-7277-487b-ba52-054c3de34f32","added_by":"auto","created_at":"2025-11-17 16:09:55","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":5331403,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7041401/v1/a637198c-7467-4042-94a8-31127a7886b8.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Prospective Study Comparing Acute Toxicity and Objective Response Rate between Simultaneous Integrated Boost and Sequential Boost Intensity-Modulated Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma","fulltext":[{"header":"Introduction","content":"\u003cp\u003eHead and neck malignancy is a disease that is remarkably heterogeneous, encompassing epithelial malignancies that develop in the paranasal sinuses, nasal cavity, oral cavity, pharynx, and larynx [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Nevertheless, there is a growing body of evidence that human papillomavirus is responsible for a specific subset of head and neck squamous cell carcinomas (HNSCC). The improvement of survival outcomes for locally advanced disease remains a significant challenge [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Radiotherapy (RT) and surgery have been the primary treatment methods for an extended period of time [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eRT is a critical component of curative treatment strategies in locally advanced HNSCC (LAHNSCC), both in the definitive phase (in the event of inoperability or to prevent mutilating surgery in oropharyngeal cancer) and in the postoperative adjuvant phase. Concomitant chemotherapy, which is typically based on cisplatin, enhances the prognosis in the definitive and postoperative adjuvant settings, particularly in the presence of extracapsular nodal spread or microscopically involved resection margins [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eHead and neck cancers (HNC) are associated with greater recurrence rates, particularly in advanced stages. Areas that received a median radiation dose of 67 Gy are responsible for 45% of loco-regional failure [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Consequently, it is postulated that certain subgroups of HNC patients would benefit from an intensified local treatment, such as the escalation of radiation dose [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. The potential to deliver higher target doses without necessarily giving higher doses to organs at risk is feasible due to technical advancements, such as the development of intensity-modulated RT (IMRT). This has made it possible to achieve more conformal dose distributions [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe sequential boost technique and the simultaneous integrated boost (SIB) are dose delivery strategies that are implemented in both volumetric modulated arc therapy and step and shot IMRT. The criteria for selecting one or the other method are typically subjective, and there are no clear recommendations for patient selection. However, the biological effects of irradiation may be advantageous for one technique or another, as determined on a case-by-case basis. Both strategies are employed in daily clinical practice [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe aim of this work was evaluation of patient\u0026rsquo;s characteristics, dosimetric analysis and plan evaluation of both intensity-modulated RT (IMRT) using sequential IMRT (IMRTSEQ) and simultaneous integrated boost (IMRT-SIB) and compare the response and acute toxicity of both arms.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cp\u003eThis prospective single blind randomized clinical comparative study was carried out on 60 patients, clinically and histologically confirmed of with LAHNSCC at Clinical Oncology Department, Tanta University Hospitals during the period from January 2022 to December 2023. An informed written consent was obtained from the patients. The study was done after approval from the Ethics Committee of the Faculty of Medicine, Tanta University Hospitals (35092/12/21).\u003c/p\u003e\u003cp\u003eInclusion criteria were age more than 18 years old, patients with locally advanced radiologically and histologically confirmed stage III, IVA squamous cell carcinoma of oral cavity, hypopharynx and larynx according to 8th edition 2018 American Joint Committee on Cancer (AJCC) Tumor, Node, Metastasis staging with no previous surgery, chemotherapy or RT [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e], performance status 0 to 2 according to Eastern Cooperative Oncology Group (ECOG) score and adequate organs' functions including (haematological, hepatic and renal function tests) [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eExclusion criteria were performance status more than 2, other malignancy including nasopharyngeal carcinoma or second primary, patients with severe arrhythmia, active infection or active peptic ulcer, uncontrolled diabetes mellitus or other uncontrolled medical illness, congestive heart failure or myocardial infarction within 6 months and patients treated with high dose corticosteroids (20mg of prednisone or equivalent) during last 6 months.\u003c/p\u003e\u003cp\u003e\u003cb\u003eRandomization\u003c/b\u003e:\u003c/p\u003e\u003cp\u003eRandomization was implemented through a computer-generated system. After obtaining the patient's consent, the list was concealed in sealed envelopes that were numbered and opened sequentially. All patients were randomly divided into two equal groups:\u003c/p\u003e\u003cp\u003eGroup (Arm) A (n = 30): was treated with SEQ-IMRT with combined total doses in phase I, II and III 70 Gy/ 35 fractions, 2 Gy/fraction along the all course, 5 days a week, in 7 weeks by 54 Gy in 27 fractions to planning target volume-low risk (PTV-LR), planning target volume- intermediate risk (PTVIR) and planning target volume- high risk (PTV-HR) in phase I followed by shrinking the field to cover only (PTV-IR) and (PTV-HR) by 60 Gy in (6 GY in 3 fractions) in phase II followed by 10 Gy in 5 fractions to PTV-HR only in phase III to be covered by 70 Gy.\u003c/p\u003e\u003cp\u003eGroup (Arm) B (n = 30) was treated with SIB-IMRT with dose 66 Gy to PTV-HR (2.2 Gy /fraction), 56 Gy to PTV-LR (1.8 Gy/ fraction) and 60 Gy to PTV-IR (2 Gy/fraction), all volumes in 30 fractions, 5 days a week, over 6 weeks.\u003c/p\u003e\u003cp\u003e\u003cb\u003ePretreatment evaluation\u003c/b\u003e:\u003c/p\u003e\u003cp\u003eAll included patients were subjected to history taking including personal history (age, sex), habits (smoking and/ or alcohol), complaint (symptoms), family history of such illness and past history of surgery and medical illness, general examination (weight, height \u0026amp; performance status according to ECOG scores) [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e] and local examination (inspection \u0026amp; palpation., cranial nerve examination, indirect laryngoscopy, fibro optic endoscopy and neck node evaluation), radiological imaging including (diagnostic magnetic resonance imaging (MRI) or high-resolution computed tomography (CT) head and neck with contrast, contrast enhanced CT chest, pelvi-abdomenal ultrasonography with CT abdomen and pelvis with contrast, bone scan, fluorodeoxyglucose positron emission tomography/computed tomography scan, electrocardiogram \u0026amp; echocardiogram, laboratory investigations (complete blood picture, renal function tests, liver function tests and serum electrolytes, invasive tests (biopsy) [meticulous clinicoradiological tumor mapping by oncology and Otorhinolaryngology consultant with histopathological evaluation of primary site and/ or enlarged lymph node, staging according (AJCC) 8th edition [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]], nutritional assessment by oncology dietitian with assessment of nutritional risk based on the use of anthropometric measurement of weight, height, body mass index (BMI) and percentage of body weight loss [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e], and pretreatment dental care.\u003c/p\u003e\u003cp\u003e\u003cb\u003eTreatment approach\u003c/b\u003e:\u003c/p\u003e\u003cp\u003eInduction chemotherapy (IC): the platinum-based regimen (TPF) was administered to all patients in three cycles. The regimen consisted of docetaxel at a dose of 75 mg/m2 administered as a 1-hour infusion on day 1, cisplatin at a dose of 75 mg/m2 administered as a 1-hour infusion on day 1, and 5-fluorouracil at a dose of 750 mg/m2 per day, administered by continuous infusion on days 1 to 5. Treatment was administered every three weeks. Weekly cisplatin at a dose of 40 mg/m2 was administered concurrently with chemotherapy. The maximal dose was restricted to 70 mg. Carboplatin was given for 9 patients who developed increase serum creatinine during CCRT by dose AUC = 2 / weekly. A pre-hydration of 2 liters of fluids was administered to the patients. The post-hydration saline with manitol was supplemented with 10 mmol of magnesium sulfate and 20 mmol of potassium chloride. A standard prophylactic anti-emetic that combines dexamethasone and 5hydroxytryptamine-3. To prevent hypersensitivity reactions and mitigate docetaxel-related cutaneous toxic effects and fluid retention, dexamethasone (at a dose of 8 mg) was administered every 12 hours for a total of six doses, commencing the night before the administration of chemotherapy (TPF) and concluding the day after. Prophylactic granulocyte colony-stimulating factor was permitted after each cycle as possible with prophylactic antibiotic.\u003c/p\u003e\u003cp\u003eRT: patients were treated in the supine position while the arms are aside. CT simulation of the head and neck was done with slice thickness 3–5 mm from vertex to D10-11 vertebrae then CT data were imported to the contouring and planning system. In accordance with the International Commission on Radiation Units and Measurements (ICRU) Report 83, the gross tumor volume (GTV) was defined by contouring gross visible tumor and enlarged or suspicious lymph nodes that were identified through clinical examination, endoscopy, and CT scan or MRI scan imaging [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. GTV with a margin of 0.5–1.0 cm for subclinical microscopic malignant disease was contoured as CTV-high risk (CTV-HR). The entire level was incorporated into CTV-HR for nodal levels that were involved. The Radiation Therapy Oncology Group (RTOG) contoured and delineated low-risk areas with potential subclinical microscopic disease as CTV-low risk (CTV-LR). These areas routinely include bilateral level II–IVA lymph nodes, while level IVB was included if level IVA was positive [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eA margin was established around the CTV to account for the uncertainties of RT planning, treatment delivery, patient set-up, and tissue deformation. This margin was designated as the planning target volume (PTV). To define each PTV-high risk (PTV-HR), PTV-intermediate risk (PTV-IR), and PTV-low risk (PTV-LR), an isotropic expansion of 5 mm was incorporated around the CTV. Within the body contour, the treatment planning system automatically cropped the PTV-HR, PTV-IR, and PTV-LR by 3 mm to disregard the initial superficial millimeter that corresponds to the build-up region, with the exception of regions where the skin was deemed to be a component of the CTV.\u003c/p\u003e\u003cp\u003eDose description: The dose prescription in group A (SEQ-IMRT) was 54 Gy in in 27 fractions to (PTV-HR, PTV-IR and PTV-LR) in phase I followed by 6 Gy in 3 fractions to (PTV-HR and PTV-IR) in phase II followed by 10 GY in 5 fractions to PTV-HR in phase III (combined total doses in phase I, II and III was 70Gy in 35 fractions, 5days of week in 7 weeks and 2 Gy/ fraction in all phases). While in group B (SIB-IMRT), dose was 66Gy to PTV-HR (2.2 Gy / fraction), 60 Gy to (PTV-IR) 2 Gy/fraction and 54 Gy to PTV-LR (1.8Gy / fraction), all were given at the same time in 30 fractions, 5 days a week, over 6 weeks. The OAR dose-constraints were prescribed as per the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) guidelines [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Dose constraints for OARs were maximum dose to the spinal cord (Dmax) \u0026lt; 45 Gy, brain stem Dmax \u0026lt; 54 Gy, mean dose to bilateral parotid \u0026lt; 26 Gy, mandible Dmax \u0026lt; 70 Gy and oral cavity Dmean \u0026lt; 40 Gy. All constraints were used for SEQ-IMRT group and SIB-IMRT in all patients.\u003c/p\u003e\u003cp\u003eTreatment planning was conducted using the Eclipse 13.7 treatment planning system from Varian. The Varian Trilogy linac, which is equipped with a 120 leaf Millennium Multileaf Collimator (MLC), produced 6 MV photon beams (MLC). Each IMRT plan used 9 coplanar beams. Initially, the treatment planning system was loaded with a set of initial optimization targets, and the beam angle optimization method was used to optimize the IMRT beam angles. The dosimetrists' expertise informed the adjustment of many beam angles. After inverse planning, the leaf sequences using sliding window technique were generated for IMRT plans. In accordance with ICRU report 83 [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eHomogeneity index (HI) as well as Conformity index (CI) were calculated for every plan. The HI was determined by subtracting the doses given to different portions of the target volume - the lowest dose to the 98 percent, the maximum dose to the 2 percent, and the median absorbed dose to the 50 percent - using the formula: HI = (D 2% - D 98%)/D 50%. When the HI was zero, it meant that the dosage distribution was very consistent. A bigger HI might mean that the dosage was either too high or that the target volume was getting an inadequate dose [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. The equation: CI = (PTVref/PTV) × (PTVref/ ref) was employed to define the CI. Vref denotes the organ volume that is contained within the prescribed isodose line. On the other hand, PTVref quantifies the coverage of PTV by this isodose line. 1 was the optimal value, and the CI ranged from 0 to 1. a prescription dose that was delivered outside the PTV was of a lower volume, as indicated by a larger CI. As the CI value approaches 1.0, the dose conformity improves [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. The coverage of PTV was set to at least 95% of the PTV volume covered by the 95% prescribed dose, minimize volume receiving \u0026gt; 110% of prescribed dose to \u0026lt; 1%. Any treatment gaps were managed as per Royal College of radiologists guidelines, aiming to complete RT within 6–7 weeks [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].\u003c/p\u003e\u003cp\u003e\u003cb\u003eFollow-up\u003c/b\u003e:\u003c/p\u003e\u003cp\u003ePatients were followed up weekly for acute radiation or chemotherapy toxicity symptoms and signs with assessment of mucositis, dermatitis, xerostomia and dysphagia at week (2, 4 and 6) of RT consistent with the common terminology criteria for adverse event (CTCAE version 5.0) and RTOG [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. The patients were encouraged to maintain their weight by modifying the diet and engaging in physical activity, such as a daily walk or home training sessions, for a duration of 10–60 minutes, three times per week, during the course of treatment. Body weight was monitored on a weekly basis. Every patient who experienced regurgitation, fungal mouth infection, or mucositis received appropriate treatment to enhance oral intake. Oral nutritional supplements were administered to patients who were unable to meet their daily nutritional needs. Clinical assessment was conducted on a monthly basis for the initial three months, three times per month for the first two years, and six times per month thereafter. This assessment was conducted through a history and examination.\u003c/p\u003e\u003cp\u003ePatients were compared as regard to clinicopathological characteristics, dosimetric parameters, acute \u0026amp; late toxicities, treatment response with comparison with different clinicopathological parameters and survival outcome including overall survival (OS), progression free survival (PFS) and disease free survival (DFS) with comparison with to clinicopathological parameters.\u003c/p\u003e\u003cp\u003e\u003cb\u003eClinical outcomes\u003c/b\u003e:\u003c/p\u003e\u003cp\u003eAssessment of tumor response: CT/MRI Head and Neck and direct laryngoscopy beside clinical examination were done at 2 months after completion of treatment to assess the response According to Response Evaluation Criteria in Solid Tumors, version 1.1 criteria (RECIST 1.1) (Appendix 5) [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. Tumor response was evaluated with different prognostic factors.\u003c/p\u003e\u003cp\u003eAssessment of toxicity: The occurrence and nature of any adverse events were recorded during CCRT. Acute toxicity (up to 6 months post-treatment) and late toxicity (beyond 6 months) from the chemoradiation including mucositis, dermatitis, dysphagia and xerostomia were assessed and graded based on (CTCAE version 5.0) and RTOG [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eAssessment of survival: OS is defined as the time from randomization to death. Any patients lost to follow up or still alive at the time of evaluation are censored [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. DFS is defined as any locoregional persistence or recurrence after RT or distant metastasis at any time or death from current disease at any time [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. PFS is the duration from the time of randomization until the first indication of disease progression or mortality. Patients who are alive at the time of evaluation or who were lost to follow-up are included in the calculation of PFS through censoring [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. Both arms were compared as regard OS, PFS and DFS with comparison with different prognostic factors.\u003c/p\u003e\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003eStatistical analysis:\u003c/h2\u003e\u003cp\u003eThe SPSS software statistical computer application for Windows, version 25.0 (Armonk, NY: IBM Corp), was employed to statistically analyze the collected data, which was organized and entered into an Excel sheet. The mean, standard deviation, and range were used to represent parametric quantitative data that was normally distributed [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. The median and interquartile ranges (25th-75th percentiles) were used to represent nonparametric quantitative data that was abnormally distributed [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. Qualitative data were presented by number and percent. The results were tabulated, grouped and statistically analyzed using the following tests: Independent t Test (t) [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e], Mann Whitney U Test (U) [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. Pearson Chi Square Test (χ²): when it was inappropriate, it was replaced by Fischer Exact or Monte Carlo Exact test [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. P value used to indicate the level of significance: P \u0026gt; = 0.05: Non-significant, P \u0026lt; 0.05: Significant and P \u0026lt; 0.001: Highly significant. OS, PFS and DFS Survival plots and cumulative survival probabilities were estimated using the Kaplan-Meier method [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e"},{"header":"Case presentation","content":"\u003cp\u003e\u003cstrong\u003eCase 1:\u003c/strong\u003e Male patient aged 48 years old, PS 0, with left trans glottic mass involving the whole length of left vocal fold (VF) with extension to vestibular band \u0026amp; anterior commissure with minimal subglottic extension (3-5mm), squamous cell carcinoma grade II, stage IVA T2N2bM0, \u0026nbsp; Patients was treated with 3 cycles induction CTH (TPF) with PR followed by CCRT with cisplatin with SIB-IMRT (66 Gy) for PTVHR, (60 Gy) for PTVIR \u0026amp; (54 Gy) for PTVLR. The PTVHR volume was 32.8 cm3, with CI= 0.95, HI= 0.06, achieved radiological CR after CCRT with G1 dermatitis \u0026amp; xerostomia, G2-3 mucositis \u0026amp; dysphagia with preserved post treatment BMI. \u003cstrong\u003eFig. 1\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCase 2:\u003c/strong\u003e Female patient aged 44 years old, PS 0, with bilateral internal jugular LNs, squamous cell carcinoma grade II, stage IVA T2N2cM0. \u0026nbsp; Patient was treated with 3 cycles induction CTH (TPF) with PR of the PCC mass and CR of LNs, followed by CCRT with cisplatin with SEQIMRT (70 Gy) for PTV HR\u0026amp; (60 GY) for PTVIR. The PTV HR volume was 88 cm3, with CI=0.98, HI=0.02, achieved radiological SD after CCRT with G2 dermatitis, xerostomia, mucositis \u0026amp; dysphagia with preserved post treatment BMI. \u003cstrong\u003eFig. 2\u003c/strong\u003e\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eIn this study, 93 patients were assessed for eligibility, 24 patients did not meet the criteria and 9 patients refused to participate in the study. The remaining 60 patients were randomly allocated into two groups (30 patients in each). All allocated patients were followed-up and analysed statistically. \u003cstrong\u003eFig. 3\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThere was no significant difference in clinicopathological parameters and type of concurrent chemotherapy between the patients for both groups of the study. \u003cstrong\u003eTable 1\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRegarding the maximum dose point (Dmax) in all PTVs, it was higher in group A than in group B but only statistically significant in PTVHR with (P = 0.013). Mean Dmax (Gy) was (72.59 \u0026plusmn; 3.33) (63.3 \u0026plusmn; 3.97) and (58.46 \u0026plusmn; 4.01) vs. (67.12 \u0026plusmn; 2.60) (62.7 \u0026plusmn; 2.76) (57.51 \u0026plusmn; 4.52) for (PTVHR, PTVIR and PTVLR) for group A and B respectively. The minimum dose point (Dmin) was lower in group A than in group B with statistical significance in PTVHR, PTV IR and PTV LR, (p= 0.003, \u0026lt; 0.001 \u0026amp; 0.013) respectively. The mean Dmin (Gy) were (65.73 \u0026plusmn; 1.80) (56.46 \u0026plusmn; 1.69) and (52.86 \u0026plusmn; 1.65) vs. (62.89 \u0026plusmn; 1.67) (57.54 \u0026plusmn; 1.72) and (53.48 \u0026plusmn; 1.86) for (PTVHR, PTVIR and PTVLR) group A \u0026amp; B respectively). There was insignificant difference regarding the mean dose (Gy) between both groups in all PTVs, in PTVHR, in PTVIR and in PTVLR, for group A and B. As regard target coverage, D95% was lower in PTVHR, PTV IR and PTV LR in group A than in group B with mean D95%(Gy) respectively with statistical significance only in PTV HR D95%, (P =0.001). \u0026nbsp;The volume of each target was insignificantly different for both groups except in PTVHR, it was significant with median volume (79.4 cm3) vs. (49.1 cm3), p= 0.012. PTV IR, median volume was (387.45cm3) vs. (457.0 cm3), and (112.5 cm3) vs. (287.0 cm3), p= 0.093 for PTV LR for group A and B respectively. \u0026nbsp;As regard dose homogeneity, HI was significantly higher in group A in all PTVs than group B, with median HI (p=\u0026lt;0.001) in PTVHR, (p= 0.005) in PTVIR and (0.2 vs. 0.1, p= 0.012) in PTVLR. CI was significantly lower in group A than in group B in all PTVs with (P \u0026lt;0.001). As regard mean dose to esophagus, it was higher in group B than group A, while mean dose to oral cavity was higher in group A than group B respectively. The mean Dmax to spinal cord was higher in group B \u0026nbsp;than in group A, while the mean dose to each parotid in both groups was nearly the same for right parotid and for left parotid for group A \u0026amp; B respectively. \u003cstrong\u003eTable 2\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll patients received 3 cycles of IC with TPF every 3 weeks, followed by CCRT. Toxicity to induction CTH (TPF), 14 patients (23.4 %) suffered from G1-2 stomatitis with oral ulceration \u0026amp; pain. Grade 2 vomiting was presented in 5 patients (8.3%). Increase in liver enzymes (1.5 to 5) upper limit normal and G1 neuropathy were in 6 patients (10%) for each toxicity. Patients developed G2 nephrotoxicity were 5 patients (8.3%) after 3 cycles induction TPF and continued their concurrent chemotherapy with carboplatin with renal support and good hydration. Grade 1 hepatotoxicity was in 6 patients (10%) and haematological toxicity with G3 neutropenia was in 13 patients (21.6%) and G1 thrombocytopenia was in 9 patients (15%). Regarding acute mucositis, it was more prominent in group B but without statistical significance, there were more G 2 and G3 mucositis in group B and A respectively. Similarly, acute dermatitis was higher in group B than group A without statistical significance. While as regard acute dysphagia, there was statistically significant more dysphagia in group B than in group A at the end of 4 and 6 weeks with (P = 0.024 and 0.32) respectively. Acute xerostomia was more in group A than in group B but statistically insignificant. Renal impairment with increase serum creatinine and sensory neuropathy due to concurrent platinum (cisplatin) were statistically insignificant for both groups. \u003cstrong\u003eTable 3\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThere was comparable weight loss due to RT toxicity for both groups of the study. As regard post treatment BMI, 5 patients (16.7%) in group A vs. 7 patients (23.3%) in group B were \u0026lt; 18.5 Kg/m2, with 3 patients (10%) needed nasogastric tube for feeding in group A vs. one patient (3.3%) in group B and only one patient in group A needed gastrostomy for feeding vs. no patients in group B after failure of oral and IV nutritional supportive treatment. Patient hospitalized for supportive treatment for RT toxicity were more in group B 12 patients (40%) vs. 10 patients (33.3%) in group A with good IV hydration, oral hygiene and nutritional supportive treatment were given according to grade of toxicity and weight loss. Compliance to treatment during CCRT, median time of interruption in the course of treatment was more in group A than in group B with which was more due to RT toxicity. There was insignificant difference between both arm of the study regarding acute (dermatitis, mucositis, dysphagia and xerostomia), where G2 acute dermatitis was more in group B than in group A while G2 acute mucositis was higher in group A than group B. Regarding G2 acute dysphagia, it was higher in group B than group A, While G2 acute xerostomia was more in group A than in group B. Acute neuropathy was comparable between both groups. Late toxicity to CCRT after 6 months of follow up, where G1-2 late dermatitis was higher in group B than in group A. While G1-2 late xerostomia and hoarseness of voice (laryngitis) were more common in group A than for group B. \u003cstrong\u003eTable 4\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAfter induction chemotherapy, OAR for all patients was 37/60 patients (61.7%) with CR in 1/60 patient (1.7%). The OAR after CCRT was 40/60 patients (66.7%) for the whole group with higher OAR for group B than group A with 23/30 patients (76.7%) vs. 17/30 patients (56.7%) respectively. Complete response was reported in 21/60 patients (35.0%) for whole with higher CR for group B 13/30 patients (43.3%) vs. 8/30 patients (26.7%) for group A. As regard the age, OAR was higher for group B (87.5% vs. 75%) for group A in age group \u0026lt; 62 years, with equal CR (100%) for both groups,. Also in age group \u0026gt;= 62 years, OAR was higher for group B (64.3% vs. 44%) for group A, with CR (35.7% vs. 11.1%) for group B and A respectively. As regard the sex, OAR was higher in group B (73.1% vs. 56.5%) for group A in male patients, with CR was reported in (42.3% vs. 30.4%) for group B \u0026amp;A respectively. For female patients, OAR was reported in (100% vs. 57.1%) for group B and A respectively, with higher CR in group B (50% vs. 14.3%) for group A. As regard the PS, OAR was equal in patients with PS0 (100%) for both groups with higher CR for group B (85.7%) vs. (60%) for group A. The same for patients with PS1, OAR was higher for group B (75%) vs. (71.4%) for group A, with also higher CR for group B(33.3%) vs. (28.6%) for group A. Also for PS2, OAR was higher for group B (63.6%) vs. (18.2%), with CR (27.3% vs. 9.1%) for group B and A respectively. As regard smoking habit, OAR was higher for group B than group A (85.7%) vs. (57.1%) respectively for non-smoker, with CR was reported in (28.6%) vs. (14.3%) for group B \u0026amp;A respectively. Also in light smoker, OAR was higher for group B (100%) vs. (90%) for group A, with CR was reported in (58.3%) vs. (50%) for group B\u0026amp; A respectively and in heavy smoker, OAR was also higher for group B (45.5%) vs. (30.8%) for group A with nearly equal CR for both groups. \u003cstrong id=\"_Toc164720423\"\u003eTable 5\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs regard the primary tumor site, OAR was higher for group B than group A in oral cavity (oral tongue cancer) patients, with no CR was reported in any group. Also in laryngeal cancer patients, OAR was higher for group B (75%) vs. (65%) for group A, with CR was in (45%) vs. (40%) for group B \u0026amp; A respectively, the same in hypopharyngeal cancer patients, OAR was higher in group B than group A with CR in (50%) vs. (0.0%) for group A. Supraglottic subsite, OAR was higher in group B (72.7%) vs. (62.5%) for group A with CR (45.5% vs. 31.3%) for group B and A respectively. Glottic subsite, OAR was nearly equal for both groups (77.8% vs. 75%), however CR was higher in group A (75%) than in group B (44.4%). pyriform sinus subsite, OAR was higher in group B (66.7%) vs. (50%) for group A, with CR was in (33.3%) in group B vs. (0.0%) for group A. Post cricoid subsite, OAR was higher for group B (100%) vs. (33.3%) for group A, with CR was in (60%) for group B vs. (0.0%) for group A. \u003cstrong\u003eTable 6\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs regard the grade, OAR and CR were equal (100%) for both groups in G1 patients. While for G2 patients OAR was (88.2% vs. 72.2%) for group B and A respectively with (41.2% vs. 22.2%) were CR in group B and A respectively. The OAR for grade 3 was also higher in group B (44.4%) than in group A (11.1%), with (2 2.2%) vs. (11.1%) were CR in group B and A respectively. T stage, OAR was higher for group B (100%) vs. (37.5%) for group A for T2 patients, with CR was in (85.7%) for group B vs. (25%) for group A, while for T3 patients, OAR was higher for group A (69.2%) than in group B (64.3%), but with higher CR for group B (35.7%) vs. (30.8%) for group A. For T4a patients, OAR was higher for group B (776.7%) vs. (55.6%) but with equal CR for both groups (22.2%) for both groups. N stage, OAR was equal (100%)l for both groups with CR was higher in group B (66.75) vs. (28.6%) for group A. No patients with N1 disease in group B for comparison with A. For N2 patients, OAR was higher in group B (66.7%) than group A (35%), (p= 0.043) with CR was in (33% vs. 20%)) for group B \u0026amp;A respectively. Tumor stage, OAR was equal (100%) and equal CR (66.7%) in both groups in stage III, while in stage IVA, OAR was higher in group B (70.8%) vs. (45.8%) in group A with CR was in (37.5%) vs. (16.7%) in group B \u0026amp;A respectively. Concurrent chemotherapy with RT, OAR was higher in group B (84.6%) vs. (60%) for group A in patients received cisplatin with CR was in (50% vs. 32%) for group B and A respectively, while in patients received carboplatin, OAR was higher for group A (40%) vs. (25%) for group B with with no CR in either group. As regard gap of interruption during RT, OAR was higher for group B (80%) vs. (78.6%) for group A in patient without gap with with CR was in (45%) vs. (42.9%) for group B \u0026amp; A respectively, also in patients with gap of interruption during RT, OAR was higher in group B (70%) vs. (37.5%) for group A with CR was in (40% vs.12.5%) for group B \u0026amp;A respectively. \u003cstrong\u003eTable 7\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll patients were followed up for median period 20 months with 19.5 months for group A \u0026amp; 20 months for group B. For whole patients, 48/60 (80%) were alive (23/30 (76.7%) patients in group A and 25/30 (83.3%) patients in group B) with 6 patients died from residual disease and 4 died from recurrent disease and rest of 2 patients died due to unrelated causes. For whole patients, median OS was not reached with mean OS was 28.12\u0026plusmn;1.28 months, while mean OS were 26.835\u0026plusmn;1.637 months and 29.627\u0026plusmn;1.747 months for group A and B respectively. The 1-year \u0026amp; 2-year OS for whole group were (98.3% \u0026amp; 61.5%) respectively, while for group A and group B, 1-year OS was 96.7 % for group A \u0026nbsp; vs. \u0026nbsp;100.0% for group B and the 2-year OS was 53.2% for group A vs. 71.2% for group B. The relation of one year OS to different clinicopathological parameters, type of concurrent chemotherapy, response state or gap of interruption during RT treatment, it was statistically insignificant. \u003cstrong\u003eFig. 3A-B\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMedian PFS was not reached for whole group with mean PFS was 26.956\u0026plusmn; 1.409 months while for group A, mean PFS was 23.455\u0026plusmn;1.37 months (95% CI 20.77-26.14) and 23.529\u0026plusmn; 1.82 months for group B. The 1-year PFS was 88.3% for whole group and 86.7% for both group of the study, while the 2-year PFS was 58.3% for whole group and 49.4% vs. 69.2% for group A and B respectively. The relation of PFS to different clinicopathological parameters, type of concurrent chemotherapy, response state or gap of interruption in RT treatment, it was statistically insignificant. \u003cstrong\u003eFig. 3C-D\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs regard DFS of patients who achieved complete response after CCRT, median DFS was not reached for whole group with mean DFS was 31.97\u0026plusmn; 1.65 months for whole group, 30.43\u0026plusmn;2.74 months for group A and 32.92\u0026plusmn;1.99 months for group B. One-year DFS was 95.2% and 2-year DFS was 84.3% for all patients, while for group A, 1-year DFS was 100.0% for group A vs. 92.3% for group B and at 2-year, DFS was 71.4% for group A vs. 92.3% for group B. The relation of DFS to different clinicopathological parameters, type of concurrent chemotherapy, response state or gap of interruption in RT treatment, it was statistically insignificant. \u003cstrong\u003eFig. 3E-F\u003c/strong\u003e\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eHypofractionated RT as SIB offers several advantages as condensed treatment schedule, reduces the overall treatment duration and enhances patient convenience and compliance [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eIn our study, no significant differences in patients' or tumor characteristics were found between both groups as regard age, sex, performance, smoking, comorbidities, tumor site, T stage, N stage, stage and grade (all p\u0026thinsp;\u0026gt;\u0026thinsp;0.05).\u003c/p\u003e\u003cp\u003eMost patients in both arms were males 76.7% vs. 86.7% with median age was 63.5 \u0026amp; 59.5 years and 60% vs. 46.7% were \u0026gt;\u0026thinsp;=\u0026thinsp;62 years. In the study of SIKDAR et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] 97% vs. 93.3% where male with median age was 60yrs vs. 57yrs for SEQ and SIB group respectively.\u003c/p\u003e\u003cp\u003eSmokers were 76.7% of each group with 43.3% vs. 36.7% were heavy smoker in SEQ \u0026amp; SIB group respectively. In the study of Tripathy et al., [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e] 76.9% vs. 81.8% were smoker in CFRT and accelerated hypofractionated RT (AHRT) respectively.\u003c/p\u003e\u003cp\u003eRegarding performance status, 63.4% of patients in our study were with good performance status (score 0 and 1) for each group. Manni et al.,[\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e] reported that 82.4% vs. 76.5% were of KPS 80 in SEQ and SIB group respectively.\u003c/p\u003e\u003cp\u003eLarynx was the most common primary tumor site (66.7%) for each group in our study. Vlacich et al., [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e] reported that oropharynx was the most common primary tumor site 71% vs. 59% for SEQ and SIB group respectively.\u003c/p\u003e\u003cp\u003eAs regard T3 disease, it was the predominant in our study, 43.3% vs. 46.7%, in SEQ and SIB group respectively. Sikdar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported that 36.4% vs. 48.5% were T3 for SEQ and SIB group respectively.\u003c/p\u003e\u003cp\u003eThe N2 disease in our study was 66.7% vs. 70% for SEQ \u0026amp; SIB group respectively. Sikdar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported that 45.5% vs. 48.5% were N2 for SEQ and SIB group respectively.\u003c/p\u003e\u003cp\u003ePatients with stage IVA disease were 80% in each group of the study. Tripathy et al., [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e] reported that 64.6% vs. 67.3% had Stage IV disease for CFRT and AHRT respectively.\u003c/p\u003e\u003cp\u003eAll patients in our study were SCC with G2 tumor was the most common in the pathology 60% vs. 56.7% for SEQ and SIB group respectively. Mani et al., [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e] reported that grade1 was the most common 353% vs. 52.9% in SEQ and SIB group respectively.\u003c/p\u003e\u003cp\u003eThe mean Dmax was 72.59 Gy vs. 62.89 Gy, (P\u0026thinsp;=\u0026thinsp;0.013), for PTVHR and 58.46 Gy vs. 53.48 Gy, for PTVLR in SEQ and SIB group repectively.\u003c/p\u003e\u003cp\u003eRakesh et al., [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e] reported that Dmax was 74.9 Gy vs. 71.98 Gy, (P\u0026thinsp;\u0026lt;\u0026thinsp;0.001) for PTVHR and 75.30 Gy vs. 71.98 Gy, (P\u0026thinsp;\u0026lt;\u0026thinsp;0.001) for PTVLR for SEQ and SIB respectively.\u003c/p\u003e\u003cp\u003eRegarding mean dose in our study, no statistical significance difference between both groups with 68.95 Gy vs. 64.6 Gy, for PTVHR and 56.50 Gy vs. 56.17 Gy, for PTVLR, for SEQ and SIB group respectively. Rakesh et al., [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e] reported that Dmean was 69.23Gy vs. 66.15 Gy, P\u0026thinsp;=\u0026thinsp;0.012 for PTVHR and 70.24 Gy vs. 67.13 Gy, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001 for PTVLR for SEQ and SIB group respectively.\u003c/p\u003e\u003cp\u003eAs regard to target coverage, mean D95% (Gy) was 67.41 Gy vs. 65.47 Gy, (p\u0026thinsp;=\u0026thinsp;\u0026lt;\u0026thinsp;0.001) for PTVHR and 54.77 Gy vs. 54.99 Gy, (p\u0026thinsp;=\u0026thinsp;0.470) for PTVLR P for SEQ and SIB group respectively.\u003c/p\u003e\u003cp\u003eSikdar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported that PTVHR D95% was equal for both SEQ and SIB group 98.18% vs. 98.08% respectively.\u003c/p\u003e\u003cp\u003eIn our study, the volume of each target was insignificantly different between both groups except for PTVHR, the median volume was 79.4 cc for SEQ group vs. 49.1 cc for SIB group, (P\u0026thinsp;=\u0026thinsp;0.012). Sikdar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported that median PTVHR volume was 197.2 cc in the SEQ arm and 174.5 cc in the SIB arm.\u003c/p\u003e\u003cp\u003eHeterogeneity in dose distribution was more in the SEQ group than for SIB group with median HI 0 was 0.16 vs. 0.06, (p\u0026thinsp;=\u0026thinsp;\u0026lt;\u0026thinsp;0.001) for PTVHR and0.2 vs. 0.1, (p\u0026thinsp;=\u0026thinsp;0.012) for PTVLR. Skidar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported more heterogenous dose in the SEQ-IMRT arm with median HI was 0.059 vs. 0.065 in SIB-IMRT.\u003c/p\u003e\u003cp\u003eWe found better conformity and sparing of organ at risk in the SIB group than in SEQ group with median CI was 0.86 vs. 0.96 for PTVHR and0.815 vs. 0.925 for PTVLR, (p\u0026thinsp;=\u0026thinsp;\u0026lt;\u0026thinsp;0.001) for all PTVs. Skidar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported that SEQ-IMRT median CI was slightly better 0.71 vs. 0.68 in SIB-IMRT.\u003c/p\u003e\u003cp\u003eAs regard mean dose (Gy) to the esophagus, it was lower for SEQ group 28.2 Gy than for SIB group 29.9 Gy, (p\u0026thinsp;=\u0026thinsp;0.391).\u003c/p\u003e\u003cp\u003eIn agreement with Vlacich et al., [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e] who reported that mean dose to esophagus was lower for SEQ group 25.6 Gy than for SIB group 27.2 Gy, (p\u0026thinsp;=\u0026thinsp;o.19). But in contrast with Grover et al., 2021 who reported that mean dose to esophagus was higher for SEQ group 26.1Gy than for SIB group 23.4Gy.\u003c/p\u003e\u003cp\u003e While for mean dose to oral cavity, it was higher for SEQ group 29.2Gy than for SIB group 26.3Gy. In contrast to Grover et al., [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e] who reported nearly equal dose to oral cavity with mean dose 37.9Gy vs. 38.5Gy for SEQ and SIB group respectively\u003c/p\u003e\u003cp\u003eThe mean Dmax to spinal cord was slightly lower for SEQ group 38.4Gy than for SIB group 39.7Gy, while Skidar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported that dose to spinal cord was 42.62 Gy vs. 41.6 Gy for SEQ and SIB group respectively.\u003c/p\u003e\u003cp\u003eThe mean dose to each parotid for both groups was nearly the same with 22.1 Gy vs. 21.6 Gy, and 21.58 Gy vs. 21.7 Gy, for right and left parotid SEQ and SIB group respectively. In contrast with Skidar et al., 2024 who reported higher dose to parotid especially SEQ group 36.14 Gy vs. 29.87 Gy, p\u0026thinsp;=\u0026thinsp;0.073 for SEQ and SIB group respectively which may be also explained by higher oropharyngeal cancer patients in this study which near site to parotid glands.\u003c/p\u003e\u003cp\u003eIn our study, after 3 cycles TPF given to all patients before CCRT, the most common adverse events were G3 neutropenia (21.6%) and G1 thrombocytopenia (15%) and G2 stomatitis (mucositis) (11.7%) compared to Zhang et al., [\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e] where Neutropenia was 15.2%, thrombocytopenia was 3.1% and mucositis was 12.1%.\u003c/p\u003e\u003cp\u003eThe G3 acute mucositis was lower in SEQ group 16.7% than in SIB group 26.7, (p\u0026thinsp;=\u0026thinsp;0.178), Also, in agree with Skidar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] who reported lower G3 mucositis in SEQ group 15.2% than that for SB group 21.2%. However, Grover et al., [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e] reported higher G3 mucositis for SEQ group 45.1% vs. 40% for SIB group, may be due to high max dose to oral cavity in SEQ group 70.2 Gy vs. 68.8Gy for SIB group, also mean dose to esophagus was higher in SEQ group 23.4Gy than SIB group 26.1Gy.\u003c/p\u003e\u003cp\u003eRegarding G3 acute dysphagia, it was lower for SEQ group 33% than SIB group 53%, (p\u0026thinsp;=\u0026thinsp;0.032). Grover et al., [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e] reported lower G3 dysphagia for SEQ-IMRT compared to SIB-IMRT 41.2%; vs. 72%, (p\u0026thinsp;=\u0026thinsp;0.006) respectively. Sikdar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] also reported lower G3 dysphagia in SEQ 24.2% than SIB group 39.4%, (p\u0026thinsp;=\u0026thinsp;0.029).\u003c/p\u003e\u003cp\u003eAs regard G3 acute dermatitis, it was 13% vs. 23%, (p\u0026thinsp;=\u0026thinsp;0.155) in SEQ and SIB group respectively. Skidar et al.,[\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported lower G3 dermatitis in SEQ group 18% than that for SIB 21%. However, Grover et al., [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e] reported higher G3 dermatitis in SEQ group 13% vs. 10% for SIB group.\u003c/p\u003e\u003cp\u003eWhile G2 xerostomia was higher for SEQ group than for SIB group 20% vs. 13.3%, respectively. Skidar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported higher G2 xerostomia in SEQ group 66.7% vs. 57.6% in SIB group.\u003c/p\u003e\u003cp\u003eThese high toxicities did not translate into significant weight loss with median weight loss 6 Kg vs. 6.4 Kg, for SEQ and SIB group respectively. Grover et al., [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e] reported that mean weight-loss was 5.6 Kg vs. 5.04 kg in SEQ and SIB group respectively.\u003c/p\u003e\u003cp\u003eNo significant difference in the need for gastrostomy with 3.3% in SEQ group vs. 0.0% in SIB group. Vlacich et al., [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e], result in higher gastrostomy tube placement in SIB group 67% vs. 62% in sequential group, may be due to higher grade3 dysphgia.\u003c/p\u003e\u003cp\u003eNeed for nasogastric tube (NGT) for feeding was higher for SEQ group 10% than SIB group 3.3%. Grover et al., [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e] reported lower percentage for NGT in SEQ group 29.4% than SIB group 40%, may be due to higher grade3 dysphagia.\u003c/p\u003e\u003cp\u003eHospitalization was lower in SEQ group 33% than in SIB group 40%. Skidar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported higher hospitalization in SEQ group 45.5% vs. 42.4% for SIB group, may be due to higher percentage of dysphagia and need for nasogasric tube.\u003c/p\u003e\u003cp\u003eAs regard to G1-2 xerostomia was higher for SEQ group 36.7% vs. 30%, for SIB group. Mani et al., [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e] reported higher late G1-2 xerostomia for SEQ group 82.3% vs. 76.5% in SIB group. Hoarseness of voice (laryngitis) was higher in SEQ group 33.3% vs. 26.7% in SIB group. Mani et al., [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e] reported lower late G1-2 laryngitis in SEQ group 58.8% vs. 64.7% in SIB group.\u003c/p\u003e\u003cp\u003eThe other late toxicities observed in our study was G1-2 dermatitis which was lower in SEQ group 26.7% vs. 30% in SIB group. Mani et al., [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e] reported higher late G1-2 dermatitis in SEQ group 35.3% vs. 29.4% in SIB group.\u003c/p\u003e\u003cp\u003eRegarding compliance to treatment, the frequency of unplanned RT breaks were higher in the SEQ group than in the SIB group with mean (RT gap) was 5days (1\u0026ndash;11 days) vs. 3.5 days (1\u0026ndash;10 days) respectively, (p\u0026thinsp;=\u0026thinsp;0.048). Grover et al., [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e] found that patients in SEQIMRT arm had less treatment-compliance with mean treatment-interruption was 4.78 days (range, 1 to 8 days) compared to SIB-IMRT arm 2.8 days (range, 1 to 10 days), (p\u0026thinsp;=\u0026thinsp;0.028).\u003c/p\u003e\u003cp\u003eIn the present study, according to the response after 2 months of finishing CCRT, SEQ group had lower OAR 56.7%, than in SIB group 76.7%. The CR was achieved in 26.7%. vs. 43% respectively. Mani et al., [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e] reported CR after 3 months of CCRT was 76.5% vs. 64.7%, in SEQ and SIB arms, respectively.\u003c/p\u003e\u003cp\u003ePartial response (PR) was 30% vs. 33.4% in SEQ and SIB group respectively. Grover et al., [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e] found similar PR 26.73% in both groups.\u003c/p\u003e\u003cp\u003eNo statistically significant difference between different clinicopathological parameters with OAR and CR except with (PS2, T2, N2 and postcricoid site), in which OAR was higher for SIB group than for SEQ group (p\u0026thinsp;=\u0026thinsp;0.030, 0.010, 0.043\u0026amp; 0.035) respectively.\u003c/p\u003e\u003cp\u003eIn our study, the median OS was not reached for whole patients and for each group with mean OS was 28 months for all patients and (26 months vs.29 months) for SEQ and SIB group respectively. For whole patients, 1-year OS was 98.3%, and at 2-years, OS was 61.5%, while for each group of the study, SEQ group had lower OS than SIB group at 1-year and 2-year of follow up 100.0% vs. 96.7% and 71.2% vs. 53.2% respectively, (p\u0026thinsp;=\u0026thinsp;0.302). Also, Stromberger et al., [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e] reported that the 3-year OS for SEQ versus SIB was 48% vs. 67% respectively. While Skidar et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported higher OS for SEQ group at the end of 1-years 78.8% vs. 75.8% in the SIB group, also at 2year OS in SEQ group was higher 66.7% vs. 60.6% in SIB group.\u003c/p\u003e\u003cp\u003eThe median PFS was not reached for whole patients and for each group of the study with mean PFS was 24 months for the whole group and 23.5 months for each group. One-year PFS was 90% for all patients, also for SEQ and SIB groups. Also, at 2-year, PFS was still 84.6% for the whole patients and 82.4% vs. 86.4% for SEQ and SIB groups respectively. Tripathy et al., [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e] reported mean PFS was 15.9 months vs. 26.9 months for CFRT and AHRT respectively.\u003c/p\u003e\u003cp\u003eThe median disease-free survival (DFS) also not reached with mean DFS was 31.9 months for whole patients, while it was lower for SEQ group 30 months vs. 32 months for SEQ group with one-year DFS was 95.2% for whole patients and at 2-years, it was 84.3%. While for each group, SEQ group had higher DFS than SIB group at 1-year 100.0% vs. 92.3% but at 2-year, DFS was higher for SIB group 92.3% vs. 71.4. Vlacich et al., [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e] reported that at 4-years, DFS was lower in SEQ group 63% than SIB group 69%. Skinder et al., [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] reported that 1-year DFS was lower for SEQ group 63.6% than SIB group 69.7%. But at 2year, DFS for both groups was equal 60.6%. Manni et al., 2022 reported higher DFS at 18 months for SEQ group 70% vs. 68% for SIB group respectively.\u003c/p\u003e\u003cp\u003eNo statistical significant difference between different clinicopathological parameters and one year (OS, PFS or DFS) was found with (p\u0026thinsp;\u0026gt;\u0026thinsp;0.05).\u003c/p\u003e\u003cp\u003eThe limitations of the study were that small number of participant patient in the study, single center study and the follow up time is not long enough.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eOur study demonstrated that the SIB-IMRT arm achieved comparable treatment outcomes and acute toxicity rates, despite its reduced total treatment duration. This decrease in treatment time not only reduces costs but also alleviates the burden of busy radiation professionals. The SIB-IMRT is well-tolerated and results in improved treatment compliance for patients with head and neck cancer. Nevertheless, it is imperative to conduct a thorough evaluation of dysphagia and dietary procedures prior to implementing this approach. In terms of overall response and toxicity, there is no significant difference between SEQ-IMRT and SIB-IMRT. However, SIB-IMRT patients exhibit a superior overall response and complete response. Significant difference was only found between both groups as regard higher grade dysphagia for SIB-IMRT. OAR and complete response between both groups were significantly affected by PS, T stage, N stage and primary tumor site, with higher OAR in SIB-IMRT than in SEQ-IMRT for patients with PS2, T2, N2 and postcricoid region. Survival outcome including overall survival, progression free survival and disease free survival were better in SIB-IMRT than in SEQ-IMRT, but without statistical significance.\u003c/p\u003e\u003cp\u003eTherefore, more studies in larger set of stage III-IVA SCC head and neck patients may possibly help in confirming the current study results and focused how to increase the survivors in that population. Superior dose painting when advanced techniques are available, such as intensity modulated arc therapy and volumetric modulated arc therapy can lead to more reduction in treatment time and more compliance of the patients with better saving of surrounding normal tissue and reduction of toxicity with SIB. Longer follow up duration for better evaluatin of survival out come and late toxicities.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eStatement of Ethics:\u003c/strong\u003e The study was done after approval from the Ethics Committee of the Faculty of Medicine, Tanta University Hospitals (35092/12/21). An informed written consent was obtained from the patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflicts of interest statement:\u003c/strong\u003e The authors have no conflicts of interest to declare.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgement:\u0026nbsp;\u003c/strong\u003eNil\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial support:\u003c/strong\u003e Authors did not receive any external fund.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability Statement:\u0026nbsp;\u003c/strong\u003eThe data supporting the present findings are contained within the manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor Contribution\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors whose names appear on the submissionmade substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; and revised it critically for important intellectual content;approved the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eCohen N, Fedewa S, Chen AY. Epidemiology and Demographics of the Head and Neck Cancer Population. Oral Maxillofac Surg Clin North Am. 2018;30:381-95.https://doi.org/10.1016/j.coms.2018.06.001\u003c/li\u003e\n\u003cli\u003eSaba NF, Pamulapati S, Patel B, et al. Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer. Cancers (Basel). 2023;15:43-67.https://doi.org/10.3390/cancers15071959\u003c/li\u003e\n\u003cli\u003eFerrari D, Ghi MG, Franzese C, et al. The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality. Front Oncol. 2020;10:7-79.https://doi.org/10.3389/fonc.2020.00007\u003c/li\u003e\n\u003cli\u003eMarur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016;91:386-96.https://doi.org/10.1016/j.mayocp.2015.12.017\u003c/li\u003e\n\u003cli\u003eNissi L, Suilamo S, Kyt\u0026ouml; E, et al. Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume. Clin Transl Radiat Oncol. 2021;27:139-46.https://doi.org/10.1016/j.ctro.2021.01.013\u003c/li\u003e\n\u003cli\u003ePagh A, Grau C, Overgaard J. Failure pattern and salvage treatment after radical treatment of head and neck cancer. Acta Oncologica. 2016;55:625-32\u003c/li\u003e\n\u003cli\u003eLeclerc M, Maingon P, Hamoir M, et al. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach. Radiother Oncol. 2013;106:33-40.https://doi.org/10.1016/j.radonc.2013.03.002\u003c/li\u003e\n\u003cli\u003eAtwell D, Elks J, Cahill K, et al. A Review of Modern Radiation Therapy Dose Escalation in Locally Advanced Head and Neck Cancer. Clin Oncol (R Coll Radiol). 2020;32:330-41.https://doi.org/10.1016/j.clon.2019.12.004\u003c/li\u003e\n\u003cli\u003eHsieh CH, Shueng PW, Wang LY, et al. Single-Institute Clinical Experiences Using Whole-Field Simultaneous Integrated Boost (SIB) Intensity-Modulated Radiotherapy (IMRT) and Sequential IMRT in Postoperative Patients With Oral Cavity Cancer (OCC). Cancer Control. 2020;27:10-73.https://doi.org/10.1177/1073274820904702\u003c/li\u003e\n\u003cli\u003eMireștean CC, Iancu RI, Iancu DPT. Simultaneous Integrated Boost (SIB) vs. Sequential Boost in Head and Neck Cancer (HNC) Radiotherapy: A Radiomics-Based Decision Proof of Concept. J Clin Med. 2023;12:43-67.https://doi.org/10.3390/jcm12062413\u003c/li\u003e\n\u003cli\u003eAmin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual: Springer; 2017.\u003c/li\u003e\n\u003cli\u003eOken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55\u003c/li\u003e\n\u003cli\u003eDi Fiore F, Lecleire S, Rigal O, et al. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol. 2006;12:85-90.https://doi.org/10.3748/wjg.v12.i26.4185\u003c/li\u003e\n\u003cli\u003eHodapp N. [The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)]. Strahlenther Onkol. 2012;188:97-9.https://doi.org/10.1007/s00066-011-0015-x\u003c/li\u003e\n\u003cli\u003eGr\u0026eacute;goire V, Evans M, Le QT, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018;126:3-24.https://doi.org/10.1016/j.radonc.2017.10.016\u003c/li\u003e\n\u003cli\u003eBrodin NP, Kabarriti R, Garg MK, et al. Systematic Review of Normal Tissue Complication Models Relevant to Standard Fractionation Radiation Therapy of the Head and Neck Region Published After the QUANTEC Reports. Int J Radiat Oncol Biol Phys. 2018;100:391-9.https://doi.org/10.1016/j.ijrobp.2017.09.041\u003c/li\u003e\n\u003cli\u003eTai DT, Oanh LT, Phuong PH, et al. Dosimetric and radiobiological comparison in head-and-neck radiotherapy using JO-IMRT and 3D-CRT. Saudi J Biol Sci. 2022;29:10-33.https://doi.org/10.1016/j.sjbs.2022.103336\u003c/li\u003e\n\u003cli\u003eChakrabarti D, Verma M, Resu AV, et al. Unscheduled Treatment Gaps in Head and Neck Cancer Radiotherapy. Bengal J Cancer. 2022;2:25-30\u003c/li\u003e\n\u003cli\u003eFreites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021;112:90-2.https://doi.org/10.1016/j.ad.2019.05.009\u003c/li\u003e\n\u003cli\u003eCox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:41-6.https://doi.org/10.1016/0360-3016(95)00060-c\u003c/li\u003e\n\u003cli\u003eEisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:28-47.https://doi.org/10.1016/j.ejca.2008.10.026\u003c/li\u003e\n\u003cli\u003ePrinja S, Gupta N, Verma R. Censoring in clinical trials: review of survival analysis techniques. Indian J Community Med. 2010;35:17-21.https://doi.org/10.4103/0970-0218.66859\u003c/li\u003e\n\u003cli\u003eKilickap S, Demirci U, Karadurmus N, et al. Endpoints in oncology clinical trials. J buon. 2018;23:1-6\u003c/li\u003e\n\u003cli\u003eWilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol. 2015;16:32-42.https://doi.org/10.1016/s1470-2045(14)70375-4\u003c/li\u003e\n\u003cli\u003eHabibzadeh F. Statistical Data Editing in Scientific Articles. J Korean Med Sci. 2017;32:1072-6.https://doi.org/10.3346/jkms.2017.32.7.1072\u003c/li\u003e\n\u003cli\u003eNajmi A, Sadasivam B, Ray A. How to choose and interpret a statistical test? An update for budding researchers. J Family Med Prim Care. 2021;10:2763-7.https://doi.org/10.4103/jfmpc.jfmpc_433_21\u003c/li\u003e\n\u003cli\u003eGuglielmetti LC, Faber-Castell F, Fink L, et al. Statistics decrypted-a comprehensive review and smartphone-assisted five-step approach for good statistical practice. Langenbecks Arch Surg. 2022;407:529-40.https://doi.org/10.1007/s00423-021-02360-0\u003c/li\u003e\n\u003cli\u003eHess AS, Hess JR. Understanding tests of the association of categorical variables: the Pearson chi-square test and Fisher\u0026apos;s exact test. Transfusion. 2017;57:877-9.https://doi.org/10.1111/trf.14057\u003c/li\u003e\n\u003cli\u003eAndrade C. Survival Analysis, Kaplan-Meier Curves, and Cox Regression: Basic Concepts. Indian J Psychol Med. 2023;45:434-5.https://doi.org/10.1177/02537176231176986\u003c/li\u003e\n\u003cli\u003eEom KY. Hypofractionated radiation therapy for head and neck cancers in the era of intensity-modulated radiation therapy. Radiat Oncol J. 2024;42:1-3.https://doi.org/10.3857/roj.2024.00178\u003c/li\u003e\n\u003cli\u003eSIKDAR D, Joseph DM, Sharma N, et al. A Prospective Randomized Study of Sequential Boost vs Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy in Locally Advanced Head and Neck Cancer. Res Sq. 2024:43-67\u003c/li\u003e\n\u003cli\u003eTripathy A, Muzumder S, Srikantia N, et al. A comparison of conventional and accelerated hypofractionated radiotherapy in definitive chemoradiation for locally advanced head and neck carcinoma: a retrospective cohort study. Radiat Oncol J. 2023;41:248-57.https://doi.org/10.3857/roj.2023.00248\u003c/li\u003e\n\u003cli\u003eMani N, Aggarwal SK, Kumar I, et al. A prospective randomized comparison of simultaneous integrated boost with sequential boost intensity-modulated radiotherapy in locally advanced head and neck cancer. J Cancer Res Ther. 2022;18:455-9.https://doi.org/10.4103/jcrt.jcrt_1358_22\u003c/li\u003e\n\u003cli\u003eVlacich G, Stavas MJ, Pendyala P, et al. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer. Radiat Oncol. 2017;12:13-76.https://doi.org/10.1186/s13014-016-0756-x\u003c/li\u003e\n\u003cli\u003eRakesh A, Goyal J, Soni S, et al. A Comparative Study of Planning and Dosimetry in Locally Advanced Head-And-Neck Cancer: Sequential versus Simultaneous Integrated Boost Methods in Intensity-Modulated Radiotherapy. J Radiat Cancer Res. 2022;13:41-7\u003c/li\u003e\n\u003cli\u003eRakesh A, Goyal J, Soni S, et al. A Comparative Study of Planning and Dosimetry in Locally Advanced Head-And-Neck Cancer: Sequential versus Simultaneous Integrated Boost Methods in Intensity-Modulated Radiotherapy. J Radiat Cancer Res. 2022;13:41-7.https://doi.org/10.4103/jrcr.jrcr_46_21\u003c/li\u003e\n\u003cli\u003eGrover A, Soni TP, Patni N, et al. A randomized prospective study comparing acute toxicity, compliance and objective response rate between simultaneous integrated boost and sequential intensity-modulated radiotherapy for locally advanced head and neck cancer. Radiat Oncol J. 2021;39:15-23.https://doi.org/10.3857/roj.2020.01018\u003c/li\u003e\n\u003cli\u003eZhang L, Jiang N, Shi Y, et al. Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis. Sci Rep. 2015;5:10-79.https://doi.org/10.1038/srep10798\u003c/li\u003e\n\u003cli\u003eStromberger C, Stsefanenka A, Kalinauskaite G, et al. Simultaneous integrated boost or sequential boost (chemo) radiation for locally advanced head and neck cancer: the same is the same? Int J Radiat Oncol Biol Phys. 2020;108:849-69\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTable 1: Clinicopathological parameters and concurrent chemotherapy with radiotherapy for both groups \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cdiv align=\"\"\u003e\n \u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"100%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 39px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAll patients (n=60)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup A\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(SEQ-IMRT)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=30)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup B\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(SIB-IMRT)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=30\u003c/strong\u003e)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"6\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eClinicopathological parameters\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge (yrs.)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;62\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e28 (46.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e12 (40%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e16 (53.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.301\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026gt;= 62\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e32 (53.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e18 (60%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e14 (46.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge (yrs.)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e61.5\u0026plusmn;8.44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e62.4 \u0026plusmn; 8.35\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e60.5 \u0026plusmn; 8.58\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e0.380\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003esex\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMale\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e49 (81.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e23 (76.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e26 (86.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.317\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eFemale\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e11 (18.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e4 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSmoking\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNever smoker\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e14 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e7 \u0026nbsp;(23.340%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.840\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eLight smoker\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e22 (36.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e10 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e12 (36.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHeavy smoker\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e24 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e13 (43.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePS (performance status)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePS0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e12 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.784\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePS1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e26 (43.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e14 (46.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e12 (40%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePS2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e22 (36.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e11 (36.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e11 (36.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCo-morbidities\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDM\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e12 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e3 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e0.053\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHTN\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e11 (18.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e4 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e0.317\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePrimary tumor site\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOral cavity\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eLarynx\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e7 (11.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.372\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e40 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e20 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e20 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHypopharynx\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e13 (21.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e8 (26.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOral tongue\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e7 (11.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e0.228\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSupra glottis region\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e27 (45.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e16 (53.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e11 (36.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e0.194\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGlottic region\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e13 (21.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e4 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e0.117\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePyriform sinus\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e5 (8.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e3 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e0.640\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePostcricoid region\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e8 (13.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e3 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e0.448\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eT stage\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eT2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e15 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e8 (26.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.949\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eT3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e27 (45.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e13 (43.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e14 (46.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eT4a\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e18 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN stage\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e16 (26.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.324\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e3 (5.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e3 (10%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e41 (68.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e20 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e21 (70%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eStage\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eIII\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e12 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e6 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e6 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eIVA\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e48 (80.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e24 (80.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e24 (80.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGrade\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e7 (11.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e3 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e4 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.918\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e35 (58.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e18 (60.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e17 (56.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e18 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e4 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"6\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eType of concurrent chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCisplatin\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e51 (85.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e25 (83.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e26 (86.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.718\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCarboplatin\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 14px;\"\u003e\n \u003cp\u003e9 (15.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e4 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003eData are presented as mean \u0026plusmn; SD or frequency (%). PS: performance status. SEQ-MRT: Sequential IMRT. SIB-IMRT: Intensity-modulated radiotherapy using simultaneous integrated boost.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 2: Dosimetric parameters of planning target volume high risk (PTV HR), planning target volume intermediate risk (PTV IR), planning target volume low risk (PTV LR) and organ at risk (OARs) for both groups\u003c/p\u003e\n\u003cdiv align=\"\"\u003e\n \u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"100%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup A\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(SEQ-IMRT)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=30)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup B\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(SIB-IMRT)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=30\u003c/strong\u003e)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePTV HR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD max (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e72.59 \u0026plusmn; 3.33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e67.12 \u0026plusmn; 2.60\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.013*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD min (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e65.73 \u0026plusmn; 1.80\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e62.89 \u0026plusmn; 1.67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.003*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD mean (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e68.95 \u0026plusmn; 2.13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e64.6 \u0026plusmn; 1.70\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.185\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD 95% (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e67.41 \u0026plusmn; 2.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e65.47 \u0026plusmn; 1.74\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eVolume (cm3)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e89.4 \u0026plusmn; 55.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e56.7 \u0026plusmn; 33.81\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.012*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHI\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e0.23 \u0026plusmn; 0.18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e0.08 \u0026plusmn; 0.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCI\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e0.82 \u0026plusmn; 0.13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e0.95 \u0026plusmn; 0.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePTV IR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD max (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e63.3 \u0026plusmn; 3.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e62.7 \u0026plusmn; 2.76\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.250\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD min (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e56.46 \u0026plusmn; 1.69\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e57.54 \u0026plusmn; 1.72\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD mean (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e59.1 \u0026plusmn; 2.85\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e58.8 \u0026plusmn; 2.63\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.462\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD 95% (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e58.5 \u0026plusmn; 2.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e58.86 \u0026plusmn; 2.82\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.381\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eVolume (cm3)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e393.1 \u0026plusmn; 165.89\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e434.3 \u0026plusmn; 164.09\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.333\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHI\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e0.24 \u0026plusmn; 0.14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e0.14 \u0026plusmn; 0.11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.005*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCI\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e0.81 \u0026plusmn; 0.14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e0.95 \u0026plusmn; 0.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePTV LR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD max (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e58.46 \u0026plusmn; 4.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e57.51 \u0026plusmn; 4.52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.127\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD min (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e52.86 \u0026plusmn; 1.65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e53.48 \u0026plusmn; 1.86\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.013*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD mean (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e56.50 \u0026plusmn; 4.59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e56.17 \u0026plusmn; 2.67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.553\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eD 95% (Gy)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e54.77 \u0026plusmn; 1.92\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e54.99 \u0026plusmn; 2.73\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.470\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eVolume (cm3)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e255.3 \u0026plusmn; 198.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e341.9 \u0026plusmn; 225.86\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.093\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHI\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e0.24 \u0026plusmn; 0.16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e0.14 \u0026plusmn; 0.11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.012*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCI\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e0.81 \u0026plusmn; 0.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e0.93 \u0026plusmn; 0.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOrgan at risk (OARs)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eEsophagus mean dose\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e28.2 \u0026plusmn; 8.59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e29.9 \u0026plusmn; 6.77\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.391\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOral cavity mean dose\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e29.2 \u0026plusmn; 6.74\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e26.3 \u0026plusmn; 8.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.137\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSpinal cord Dmax\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e38.4 \u0026plusmn; 4.09\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e39.7 \u0026plusmn; 6.11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.338\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eRight parotid mean dose\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e22.1 \u0026plusmn; 3.22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e21.6 \u0026plusmn; 4.26\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.676\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 39px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eLeft parotid mean dose\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 26px;\"\u003e\n \u003cp\u003e21.58 \u0026plusmn; 4.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e21.7 \u0026plusmn; 4.31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 13px;\"\u003e\n \u003cp\u003e0.897\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003eData presents as mean \u0026plusmn; SD or frequency (%). SEQ-MRT: Sequential IMRT. SIB-IMRT: Intensity-modulated radiotherapy using simultaneous integrated boost.* significant as P-value \u0026le; 0.05.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cspan dir=\"RTL\"\u003e\u003cbr\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan dir=\"RTL\"\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003eTable\u0026nbsp;3: Grades of acute mucositis, grades of acute dysphagia, grades of acute dermatitis and grades of acute xerostomia during CCRT for both groups\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"100%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" style=\"width: 47px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup A (SEQ-MRT) (n=30)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup B\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(SIB-IMRT) (n=30\u003c/strong\u003e)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 15px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"11\" style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGrades of acute mucositis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e22 (73.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e20 (66.7 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 15px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.886\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e7 (23.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e9 (30 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e1 (3.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e1 (3.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW4\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e0 (0.00%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e0 (0.00%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 15px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.390\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e14 (46.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e10 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e14 (46.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e15 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW6\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e0 (0.00%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e0 (0.00%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 15px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.178\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e2 (6.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e18 (60.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e20 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e8 (26.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"11\" style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGrades of acute dysphagia\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e20 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e13 (43.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 15px;\"\u003e\n \u003cp\u003e0.146\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e16 (53.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e1 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e1 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW4\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 15px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.024*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e17 (56.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e13 (43.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e4 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e10 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW6\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e0 (0.00%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e0 (0.00%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 15px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.032*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e10 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e10 (33.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e12 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e10 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e16 (53.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"9\" style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGrades of acute dermatitis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e21 (70%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e18 (60%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e0.417\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e9 (30%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e12 (40%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW4\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e11 (36.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e4 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 15px;\"\u003e\n \u003cp\u003e0.113\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e12 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e16 (53.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e10 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW6\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e0 (0.00%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e0 (0.00%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 15px;\"\u003e\n \u003cp\u003e0.155\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e14 (46.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e12 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e16 (53.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e4 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"9\" style=\"width: 13px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGrades of acute xerostomia\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e28 (93.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e26 (86.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e0.671\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e2 (6.7 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e4 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW4\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e16 (53.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e17 (56.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 15px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e0.798\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e14 (46.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e12 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e1 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" style=\"width: 16px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eW6\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 15px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e0.726\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e17 (56.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e16 (53.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e6 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e4 (13.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 16px;\"\u003e\n \u003cp\u003e0 (0.0 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19px;\"\u003e\n \u003cp\u003e1 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eData presents as mean \u0026plusmn; SD or frequency (%), SEQ-MRT:\u0026nbsp;Sequential IMRT. SIB-IMRT:\u0026nbsp;Intensity-modulated radiotherapy using simultaneous integrated boost.* significant as P-value \u0026le; 0.05.\u003cspan dir=\"RTL\"\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003eTable 4: Body mass index after CCRT, compliance to treatment during CCRT, post treatment acute toxicity and late toxicity for both groups\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"100%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" style=\"width: 41px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup A (SEQIMRT) (n=30)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup B (SIB-\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eIMRT) (n=30\u003c/strong\u003e)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" rowspan=\"3\" style=\"width: 19px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePre BMI (Kg/m2)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt; 18.5\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e1 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 10px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 21px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e18.5 to 24.9\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e28 (93.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e28 (93.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 21px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e25 to 29.9\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e1 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" rowspan=\"3\" style=\"width: 19px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePost BMI (Kg/m2)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 21px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt; 18.5\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0.537\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 21px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e18.5 to 24.9\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e25 (83.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e22 (73.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 21px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e25 to 29.9\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e0 (0.00%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e1 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" style=\"width: 41px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eWeight Loss (Kg)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e6.23 \u0026plusmn; 2.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e5.5 \u0026plusmn; 2.43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0.550\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" style=\"width: 41px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGastrostomy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e1 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" style=\"width: 41px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNasogastric tube\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e3 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e1 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0.612\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" style=\"width: 41px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHospitalization (RTH toxicity)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e10 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e12 (40%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0.592\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" style=\"width: 41px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eInturruption (days)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e5.0 \u0026plusmn; 4.07\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e3.5 \u0026plusmn; 3.04\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0.509\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"6\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePost treatment acute toxicity\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAcute Dermatitis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e16 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e13 (43.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0.684\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e11 (36.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e12 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e3 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAcute mucositis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e16 ( 53.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e19 (63.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0.649\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e10 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e4 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAcute dysphagia\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e19 (63.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e15 (50%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0.444\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e10 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAcute xerostomia\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e8 (26.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e5 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0.093\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e14 (46.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e22 (73.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e8 (26.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e3 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNeuropathy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e19 (63.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e18 (60.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 10px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e8 (26.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e3 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e1 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"6\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePost treatment late toxicity\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eLate dermatitis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e22 (73.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e21 (70.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 10px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e6 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eLate xerostomia\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e19 (63.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e21 (70.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 10px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e8 (26.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e3 (10%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eLaryngitis (hoarseness of voice)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e17 (56.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e22 (73.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0.440\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e6 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e4 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 89px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 3px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 96px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 108px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 107px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 48px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eData presents as mean \u0026plusmn; SD or frequency (%). BMI:\u0026nbsp;body mass index, SEQ-MRT: Sequential IMRT. SIB-IMRT: Intensity-modulated radiotherapy using simultaneous integrated boost.\u003cspan dir=\"RTL\"\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003eTable 5: Response to concurrent chemo radiotherapy for both groups, according to age, sex, performance status and smoking for both groups\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"104%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAll patients (n=60)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" style=\"width: 32px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup A(SEQ-IMRT)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=30)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 23px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup B (SIB-\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eIMRT) (n=30\u003c/strong\u003e)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e21 (35.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" style=\"width: 32px;\"\u003e\n \u003cp\u003e8 (26.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 23px;\"\u003e\n \u003cp\u003e13 (43.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 8px;\"\u003e\n \u003cp\u003e0.384\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e19 (31.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" style=\"width: 32px;\"\u003e\n \u003cp\u003e9 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 23px;\"\u003e\n \u003cp\u003e10 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e17 (28.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" style=\"width: 32px;\"\u003e\n \u003cp\u003e11 (36.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 23px;\"\u003e\n \u003cp\u003e6 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e3 (5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" style=\"width: 32px;\"\u003e\n \u003cp\u003e2 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 23px;\"\u003e\n \u003cp\u003e1 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR) (CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e40 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" style=\"width: 32px;\"\u003e\n \u003cp\u003e17 (56.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 23px;\"\u003e\n \u003cp\u003e23 (76.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e0.1000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e20 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" style=\"width: 32px;\"\u003e\n \u003cp\u003e13 (43.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 23px;\"\u003e\n \u003cp\u003e7 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge \u0026lt;62 Y\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"9\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge \u0026gt;=62 Y\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ (n=12)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=16)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ (n=18)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 21px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=14)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e6 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e8 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.627\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (11.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 21px;\"\u003e\n \u003cp\u003e5 (35.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 8px;\"\u003e\n \u003cp\u003e0.408\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e3 (5.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e6 (37.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e6 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 21px;\"\u003e\n \u003cp\u003e4 (28.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e3 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e2 (12.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e8 (44.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 21px;\"\u003e\n \u003cp\u003e4 (28.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (11.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 21px;\"\u003e\n \u003cp\u003e1 (7.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR) (CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e9 (75.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e14 (87.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.393\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e8 (44.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 21px;\"\u003e\n \u003cp\u003e9 (64.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e0.265\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e3 (5.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e2 (12.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e10 (55.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 21px;\"\u003e\n \u003cp\u003e5 (35.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMale\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"9\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eFemale\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ (n=23)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=26)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ (n=7)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 21px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=4)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e7 (30.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e11 (42.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.656\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e1 (14.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 8px;\"\u003e\n \u003cp\u003e0.231\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e6 (26.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e8 (30.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3 (42.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e8 (34.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e6 (23.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3 (42.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e0.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e2 (8.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e1 (3.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e0.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR) (CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e13 (56.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e19 (73.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.224\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e4 (57.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8px;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e100.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e0.125\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 22px;\"\u003e\n \u003cp\u003e10 (43.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e7 (26.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3 (42.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e0.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 30px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePS 0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" style=\"width: 27px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePS 1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 29px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePS 2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=5)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=7)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=14)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=12)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=11)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=11)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e3 (60.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e6 (85.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.310\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (28.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 10px;\"\u003e\n \u003cp\u003e4 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.656\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e1 (9.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e3 (27.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 8px;\"\u003e\n \u003cp\u003e0.132\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e1 (14.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e6 (42.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 10px;\"\u003e\n \u003cp\u003e5 (41.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e1 (9.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (36.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (28.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e7 (63.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (36.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 10px;\"\u003e\n \u003cp\u003ec1 (8.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e2 (18.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR) (CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e5 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e7 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e10 (71.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 10px;\"\u003e\n \u003cp\u003e9 (75.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.838\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e2 (18.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e7 (63.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.030*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (28.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 10px;\"\u003e\n \u003cp\u003e3 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 12px;\"\u003e\n \u003cp\u003e9 (81.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (36.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponse state\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 30px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon smoker\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" style=\"width: 27px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eLight smoker\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 29px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHeavy smoker\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=7)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=7)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=10)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=12)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=13)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=11)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e1 (14.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e4 (28.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.112\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 9px;\"\u003e\n \u003cp\u003e5 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e7 (58.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.263\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e2 (15.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (18.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 8px;\"\u003e\n \u003cp\u003e0.605\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e3 (42.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e2 (28.6%)\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e5 (41.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e2 (15.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e3 (27.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e3 (42.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e7 (53.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e6 (54.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e1 (14.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e2 (15.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e4 (57.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e6 (85.7%)\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.237\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 9px;\"\u003e\n \u003cp\u003e9 (90.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e12 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.262\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e4 (30.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e5 (45.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e0.459\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e3 (42.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11px;\"\u003e\n \u003cp\u003e1 (14.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e9 (69.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e6 (54.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eData presents as frequency (%).CR: complete response, PR: partial response, SD: stationary disease, PD: progressive disease, OAR: overall response. SEQ: Sequential IMRT. SIB: Intensity-modulated radiotherapy using simultaneous integrated boost.* Significant as P-value \u0026le; 0.05.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 6: Response to concurrent chemoradiotherapy according to primary tumor site, supraglottic sub site, glottic sub site, pyriform sinus subsite and postcricoid sub site for both groups\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"104%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"10\" style=\"width: 79px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eprimary tumor site\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" style=\"width: 25px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOral cavity (oral tongue)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 25px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eLarynx\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 28px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHypopharynx\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=5)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=2)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=20)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=20)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=5)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=8)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 6px;\"\u003e\n \u003cp\u003e0.792\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e8 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e9 (45.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 6px;\"\u003e\n \u003cp\u003e0.785\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e4 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.121\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e2 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e5 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e6 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e3 (37.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e2 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e7 (35.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e5 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e1 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e1 (12.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(OAR)(CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e2 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 6px;\"\u003e\n \u003cp\u003e0.809\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e13 (65.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e15 (75.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 6px;\"\u003e\n \u003cp\u003e0.490\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e7 (87.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.071\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e3 (60.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 8px;\"\u003e\n \u003cp\u003e7 (35.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9px;\"\u003e\n \u003cp\u003e5 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e3 (60.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e1 (12.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"10\" style=\"width: 79px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSupra glottis region\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ(n=16)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=11)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e5 (31.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e5 (45.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.743\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e5 (31.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e3 (27.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e6 (37.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e3 (27.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e10 (62.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e8 (72.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.580\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e6 (37.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e3 (27.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"10\" style=\"width: 79px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGlottic region\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ(n=4)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB(n=9)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e3 (75.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e4 (44.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.283\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e3 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e1 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e2 (22.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR)(CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e3 (75.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e7 (77.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.913\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e1 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e2 (22.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"10\" style=\"width: 79px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePyriform sinus region\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ(n=2)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB(n=3)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e1 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.569\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e1 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e1 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e1 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e1 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR)(CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e1 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e2 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.709\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e1 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e1 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"10\" style=\"width: 79px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePost cricoid region\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ(n=3)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB(n=5)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e3 (60.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.076\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e1 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e2 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e2 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR)(CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e1 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e5 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.035*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 34px;\"\u003e\n \u003cp\u003e2 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 37px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eData presents as mean \u0026plusmn; SD or frequency (%).SEQ: Sequential IMRT. SIB: Intensity-modulated radiotherapy using simultaneous integrated boost. CR: Complete response, PR: Partial response, SD: Stationary disease, PD: Progressive disease, OAR: Overall response, *: significant as P value \u0026le; 0.05.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 7: Response to concurrent chemoradiotherapy according to grade, T stage, \u0026nbsp;N stage, stage, type of concurrent chemotherapy and gap of interruption for both groups\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"107%\" class=\"fr-table-selection-hover\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"15\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGrade\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponse state\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 25px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eG3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=3)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=4)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=18)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=17)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=9)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=9)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e3 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e4 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (22.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e7 (41.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 6px;\"\u003e\n \u003cp\u003e0.344\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (11.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (22.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.381\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e9 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e8 (47.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (22.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e5 (27.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e2 (11.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e6 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e4 (44.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e2 (22.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e1 (11.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e3 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e4 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e13 (72.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e15 (88.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 6px;\"\u003e\n \u003cp\u003e0.237\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (11.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e4 (44.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.114\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e5 (27.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e2 (11.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e8 (88.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e5 (55.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"14\" style=\"width: 82px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eT stage\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" style=\"width: 28px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eT2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 25px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eT3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 28px;\"\u003e\n \u003cp\u003eT4a\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=8)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=7)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=13)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=14)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=9)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=9)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e6 (85.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.073\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (30.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e5 (35.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 6px;\"\u003e\n \u003cp\u003e0.756\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e2 (22.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (22.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.637\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e1 (12.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e1 (14.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e5 (38.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (28.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e3 (33.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e5 (55.6 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e4 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (30.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (28.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e3 (33.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (22.2 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e1 (12.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (7.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (11.1 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR) (CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e3 (37.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e7 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.010*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e9 (69.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e9 (64.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 6px;\"\u003e\n \u003cp\u003e0.785\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e5 (55.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e7 (76.7 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.317\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e5 (62.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (30.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e5 (35.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (43.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (23.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"14\" style=\"width: 82px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN stage\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" style=\"width: 28px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNO\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 25px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" style=\"width: 28px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=7)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=9)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=3)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=0)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003eP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(n=20)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=21)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e2 (28.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e6 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.131\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e2 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e-\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e4 (20.0 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e7 (33.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"4\" style=\"width: 7px;\"\u003e\n \u003cp\u003e0.241\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e5 (71.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e3 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e1 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e3 (15.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e7 (33.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e11 (55.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e6 (28.6 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e2 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e1 (4.8 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(OAR) (CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e7 (%)100.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e9 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e3 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e-\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e7 (35.0 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e14 (66.7 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.043*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 9px;\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003cp\u003e65.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e7 (33.3 %)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"14\" style=\"width: 82px;\"\u003e\n \u003cp\u003e\u003cstrong\u003estage for both groups\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"7\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eStage III\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"7\" style=\"width: 38px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eStage IV\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ (n=6)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=4)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ (n=24)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=24)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e4 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e4 (66.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"4\" style=\"width: 10px;\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e4 (16.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e9 (37.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"4\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.285\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e2 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e2 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e7 (29.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e8 (33.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e11 (45.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e6 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e`PD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (8.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e1 (4.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(OAR)(CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e6 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e6 (100.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e11 (45.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e17 (70.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.079\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e13 (54.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e7 (29.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"14\" style=\"width: 82px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eType of concurrent chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"7\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCisplatin\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"7\" style=\"width: 38px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCarboplatin\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e8 (32.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e13 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"4\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0.136\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"4\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.638\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e7 (28.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e9 (34.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e1 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e10 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e4 (15.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e1 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e2 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e1 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(OAR)(CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e15 (60.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e22 (84.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0.049\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e1 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.635\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e10 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e4 (15.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3 (60.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e3 (75.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"14\" style=\"width: 82px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGap of interruption\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"7\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNo gap\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"7\" style=\"width: 38px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGap \u0026gt;=1 day\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ (n=14)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB (n=20)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSEQ(n=16)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSIB(n=10)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e6 (42.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e9 (45.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"4\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0.991\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (12.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e4 (40.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"4\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.315\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e5 (35.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e7 (35.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e4 (25.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e3 (30.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e3 (21.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e4 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e8 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e2 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (12.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e1 (10.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponsive (OAR)(CR+PR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e11 (78.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e16 (80.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"2\" style=\"width: 10px;\"\u003e\n \u003cp\u003e0.919\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e6 (37.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e7 (70.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" rowspan=\"2\" style=\"width: 11px;\"\u003e\n \u003cp\u003e0.107\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNon responsive (SD+PD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 15px;\"\u003e\n \u003cp\u003e3 (21.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 17px;\"\u003e\n \u003cp\u003e4 (20.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 14px;\"\u003e\n \u003cp\u003e10 (62.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 12px;\"\u003e\n \u003cp\u003e3 (30.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eData presents as mean \u0026plusmn; SD or frequency (%).SEQ: Sequential IMRT. SIB: Intensity-modulated radiotherapy using simultaneous integrated boost. CR: Complete response, PR: Partial response, SD: Stationary disease, PD: Progressive disease, OAR: Overall response, *: significant as P value \u0026le; 0.05.\u0026nbsp;\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"medical-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"medo","sideBox":"Learn more about [Medical Oncology](https://www.springer.com/journal/12032)","snPcode":"12032","submissionUrl":"https://submission.nature.com/new-submission/12032/3","title":"Medical Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Acute Toxicity, Response Rate, Simultaneous Integrated Boost, Sequential Boost Intensity-Modulated Radiation Therapy, Advanced Head and Neck Squamous Cell Carcinoma","lastPublishedDoi":"10.21203/rs.3.rs-7041401/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7041401/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003ePurpose\u003c/h2\u003e\u003cp\u003ePatients with locally advanced head and neck squamous cell carcinoma (HNSCC) were included for evaluation of patient\u0026rsquo;s characteristics, dosimetric analysis and plan evaluation of both intensity-modulated radiotherapy (RT) using simultaneous integrated boost (SIB-IMRT) and sequential IMRT (IMRTSEQ) and compare the response and acute toxicity of both arms.\u003c/p\u003e\u003ch2\u003eMaterials and Methods\u003c/h2\u003e\u003cp\u003eThis prospective single blind randomized clinical comparative study was carried out on 60 patients, clinically and histologically confirmed of locally advanced HNSCC at Clinical Oncology Department, Tanta University Hospitals. All patients were randomly divided into two equal groups: Group A was treated with SEQ-IMRT and group B was treated with SIB-IMRT. All patients received 3 cycles induction chemotherapy with (Docetaxel or Taxotere), Platinum and 5-fluorouracil followed by concurrent chemo RT with cisplatin or carboplatin.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e\u003cp\u003ePerformance status 2; Organ at risk (OAR) was higher for group B (63.6%) vs. (18.2%), (p\u0026thinsp;=\u0026thinsp;.030). post cricoid subsite, OAR was higher for group B (100%) vs. (33.3%) for group A, (p\u0026thinsp;=\u0026thinsp;0.035). For N2 patients, OAR was higher in group B (66.7%) than group A (35%), (p\u0026thinsp;=\u0026thinsp;0.043) with CR was in (33% vs. 20%)) for group B \u0026amp;A respectively, (p\u0026thinsp;=\u0026thinsp;0.241).\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e\u003cp\u003eThe SIB-IMRT arm, with shorter total treatment duration, resulted in comparable treatment outcomes and acute toxicity rates. This reduction in treatment time not only reduces costs but also decreases the workload of busy radiation. The SIB-IMRT is well-tolerated with better treatment-compliance for head and neck cancer patients.\u003c/p\u003e","manuscriptTitle":"Prospective Study Comparing Acute Toxicity and Objective Response Rate between Simultaneous Integrated Boost and Sequential Boost Intensity-Modulated Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-08-19 11:29:04","doi":"10.21203/rs.3.rs-7041401/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-08-27T00:30:12+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-08-18T19:30:16+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-08-17T14:48:35+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"122318395409486950829116950804023114581","date":"2025-08-14T16:39:25+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-08-14T05:33:02+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"145787391967398328077829953123180333526","date":"2025-08-12T03:06:48+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"167744758665364441768574093033764435742","date":"2025-08-11T04:45:15+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-08-10T22:46:44+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-07-09T01:09:40+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-07-09T01:08:41+00:00","index":"","fulltext":""},{"type":"submitted","content":"Medical Oncology","date":"2025-07-03T21:07:29+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"medical-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"medo","sideBox":"Learn more about [Medical Oncology](https://www.springer.com/journal/12032)","snPcode":"12032","submissionUrl":"https://submission.nature.com/new-submission/12032/3","title":"Medical Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"751c86a1-699c-4294-a89a-df0cf3f68aad","owner":[],"postedDate":"August 19th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-11-17T16:05:17+00:00","versionOfRecord":{"articleIdentity":"rs-7041401","link":"https://doi.org/10.1007/s12032-025-03110-8","journal":{"identity":"medical-oncology","isVorOnly":false,"title":"Medical Oncology"},"publishedOn":"2025-11-15 15:56:59","publishedOnDateReadable":"November 15th, 2025"},"versionCreatedAt":"2025-08-19 11:29:04","video":"","vorDoi":"10.1007/s12032-025-03110-8","vorDoiUrl":"https://doi.org/10.1007/s12032-025-03110-8","workflowStages":[]},"version":"v1","identity":"rs-7041401","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7041401","identity":"rs-7041401","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}